1
|
Fleischmann R, Blanco R, Van den Bosch F, Bessette L, Song Y, Penn SK, McDearmon-Blondell E, Khan N, Chan K, Mysler E. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatol Ther 2024:10.1007/s40744-024-00658-1. [PMID: 38498140 DOI: 10.1007/s40744-024-00658-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Accepted: 02/21/2024] [Indexed: 03/20/2024] Open
Abstract
INTRODUCTION This study aimed to describe the long-term efficacy and safety of upadacitinib and adalimumab through 228 weeks following immediate switch to the alternate therapy with a different mechanism of action (MoA) in patients with rheumatoid arthritis (RA) not achieving treatment goals with their initial randomized therapy in the ongoing phase 3 SELECT-COMPARE study. METHODS Patients with non-response or incomplete response to initially prescribed upadacitinib 15 mg once daily or adalimumab 40 mg every other week were switched to the alternate therapy by week 26. Efficacy was evaluated through 228 weeks post-switch using validated outcome measures, including Clinical Disease Activity Index (CDAI) low disease activity (LDA; ≤ 10)/remission (≤ 2.8); 28-joint Disease Activity Score based on C-reactive protein ≤ 3.2/< 2.6; ≥ 20%/50%/70% improvement in American College of Rheumatology (ACR) response criteria; and change from baseline in ACR core components. Data are reported as observed. Safety was assessed by treatment-emergent adverse events (TEAEs) through week 264. RESULTS Of patients initially randomized to upadacitinib and adalimumab, 38.7% and 48.6%, respectively, switched to the alternate therapy by week 26. Clinically relevant improvements in all efficacy measures were observed through 228 weeks post-switch and were generally similar between groups, with small numeric differences mostly in favor of switching to upadacitinib. CDAI remission was achieved by 32.7% and 28.6% of initial non-responders, and 27.5% and 27.3% of incomplete responders, while CDAI LDA was achieved by 76.9% and 72.9% of non-responders, and 72.5% and 72.7% of incomplete responders switching to upadacitinib and to adalimumab, respectively. TEAE rates were similar between groups, although herpes zoster infection, lymphopenia, and creatine phosphokinase elevation were more frequent when switching to upadacitinib. No new safety signals were identified. CONCLUSION Switching to a different MoA may provide long-term benefit to patients with RA not achieving treatment goals with their initial therapy, with acceptable safety profiles. TRIAL REGISTRATION NCT02629159.
Collapse
Affiliation(s)
- Roy Fleischmann
- Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX, 75231, USA.
| | - Ricardo Blanco
- Rheumatology Division, Hospital University Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain
| | - Filip Van den Bosch
- VIB-UGent Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
| | | | | | | | | | | | | | - Eduardo Mysler
- Organizacion Medica de Investigación, Rheumatology, Buenos Aires, Argentina
| |
Collapse
|
2
|
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Carter K, Stakias V, Lippe R, Drogaris L, Soliman AM, Chen MM, Padilla B, Kivitz A. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatol Ther 2024:10.1007/s40744-024-00657-2. [PMID: 38498139 DOI: 10.1007/s40744-024-00657-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 02/14/2024] [Indexed: 03/20/2024] Open
Abstract
INTRODUCTION Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and/or 1-2 biologic DMARDs (bDMARD-IR). Herein, we report results through 100 weeks of treatment. METHODS KEEPsAKE 2 is a global phase 3 trial. Patients with active PsA were randomized 1:1 to double-blind subcutaneous risankizumab 150 mg or placebo (weeks 0, 4, and 16). At week 24, all patients received open-label risankizumab every 12 weeks until end of study. Efficacy endpoints included achieving ≥ 20% improvement in PsA symptoms using American College of Rheumatology criteria (ACR20), attaining minimal disease activity (MDA; meeting ≥ 5/7 criteria of low disease activity and extent), and improving in other measures. RESULTS At the cutoff date, 345/443 (77.9%) patients were ongoing in the study. ACR20 was achieved in 57.1% and 52.5% of the continuous risankizumab and placebo/risankizumab cohorts, respectively, at week 100 and in 60.0% and 55.8%, respectively, at week 52. In week 52 responders, maintenance of ACR20 at week 100 was achieved in 74.8% (continuous risankizumab) and 78.7% (placebo/risankizumab) of patients. In the continuous risankizumab and placebo/risankizumab cohorts, respectively, MDA was achieved by 33.0% and 33.3% of patients at week 100 and by 27.2% and 33.8% at week 52. Among MDA responders at week 52, maintenance of MDA response was achieved by 83.6% and 73.0% of the continuous risankizumab and placebo/risankizumab cohorts, respectively. Risankizumab was well tolerated through week 100. CONCLUSIONS Risankizumab demonstrated durable efficacy and tolerability through 100 weeks; most patients who achieved ACR20 and MDA responses at week 52 maintained this achievement through week 100. There were no new safety signals in patients who had csDMARD-IR and bDMARD-IR. TRIAL REGISTRATION ClinicalTrials.gov NCT03671148.
Collapse
Affiliation(s)
- Andrew Östör
- Department of Medicine, Monash University, Clayton, VIC, Australia.
- Department of Medicine, Australian National University, Canberra, ACT, Australia.
- Emeritus Research, Level 2/1180 Toorak Rd, Camberwell, VIC, 3124, Australia.
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Department of Internal Medicine and Pediatrics, VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Kim Papp
- Probity Medical Research and Alliance Clinical Trials, Waterloo, ON, Canada
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | | | - Ricardo Blanco
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL (Immunopathology Group), Santander, Spain
| | - Jacob Aelion
- Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, USA
| | | | | | | | | | | | | | | | - Alan Kivitz
- Altoona Center for Clinical Research, Duncansville, PA, USA
| |
Collapse
|
3
|
De Mits S, Willems T, Calders P, Danneels L, Varkas G, Van den Bosch F, Elewaut D, Carron P. Maximal exercise tolerance, objective trunk strength and mobility measurements in axial spondyloarthritis. J Rheumatol 2024:jrheum.2023-1046. [PMID: 38490674 DOI: 10.3899/jrheum.2023-1046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2024]
Abstract
OBJECTIVE Although exercise therapy is safe, effective and recommended within the nonpharmacological treatment in axial spondyloarthritis (axSpA), guidelines regarding type and dosage lack. Insufficient knowledge about physical and physiological parameters makes designing effective exercise programs challenging. Therefore, the goal was to simultaneously assess trunk strength, spinal mobility and the axSpA patients' cardiorespiratory fitness. METHODS In a cross-sectional study, 58 axSpA patients (mean age:40.8years, 50% males, mean symptom duration:10.3years) performed maximal cervical and trunk mobility and isometric strength tests in all planes (David Back Concepts devices) and a maximal cardiopulmonary bicycle exercise test (n=25). Mobility and strength data were compared to healthy reference data. Cut-off values for clinical CPET interpretation were used to judge normality. Patients were compared based on radiographic involvement and symptom duration. RESULTS Both strength (p≤0,017) and mobility (p≤0,001) were significantly lower for the axSpA patients compared to reference. Strength deficits were comparable between the radiographic and nonradiographic group (p>0,05 except trunk extension p=0,029), whereas mobility showed higher deficits in the radiographic group (cervical extension p=0,017 and rotation p=0,005 and trunk extension p=0,034 and rotation p=0,029), regardless of symptom duration. Similarly, symptom duration positively affected oxygen pulse (p=0,027), relative anaerobic threshold (p=0,020) and aerobic capacity (p=0,021). CONCLUSION Strength is more affected than mobility when compared to healthy controls. Likewise, mainly the metabolic component of aerobic capacity is impaired, affecting cardiopulmonary fitness. These findings indicate that future personalized exercise programs in axSpA patients should incorporate exercises for cardiopulmonary fitness next to strength and mobility training.
Collapse
Affiliation(s)
- Sophie De Mits
- S. De Mits (PT, PhD) - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Smart Space, Ghent University Hospital, Ghent, Belgium
| | - Tine Willems
- T.M. Willems (PT, PhD) - Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium
| | - Patrick Calders
- P. Calders (PhD) - Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium
| | - Lieven Danneels
- L. Danneels (PT, PhD) - Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium
| | - Gaëlle Varkas
- G. Varkas (MD, PhD) - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Filip Van den Bosch
- F. Van den Bosch (MD, PhD) - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Dirk Elewaut
- D. Elewaut (MD, PhD) - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Philippe Carron
- P. Carron (MD, PhD) - Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| |
Collapse
|
4
|
Vereecke E, Jans L, Herregods N, Chen M, Jaremko JL, Laloo F, Carron P, Varkas G, de Hooge M, Van den Bosch F, Elewaut D, Morbée L. Association of anatomical variants of the sacroiliac joint with bone marrow edema in patients with axial spondyloarthritis. Skeletal Radiol 2024; 53:507-514. [PMID: 37682337 DOI: 10.1007/s00256-023-04435-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 08/17/2023] [Accepted: 08/17/2023] [Indexed: 09/09/2023]
Abstract
OBJECTIVE To determine the prevalence of sacroiliac joint variants in patients with axial spondyloarthritis (axSpA) using MRI-based synthetic CT images and to evaluate their relationships with the presence of bone marrow edema, as this may potentially complicate diagnosing active sacroiliitis on MRI in patients with suspected axSpA. METHODS 172 patients were retrospectively included. All patients underwent MRI because of clinical suspicion of sacroiliitis. The diagnosis of axSpA was made by a tertiary hospital rheumatologist. Two readers independently determined the presence of bone marrow edema and the presence of one or more of the nine known sacroiliac joint (SIJ) variants. RESULTS SIJ variants were common in axSpA patients (82.9%) and the non-SpA group (85.4%); there were no significant differences in prevalence. Bone marrow edema was frequently found in axSpA (86.8%) and non-SpA patients (34%). AxSpA patients with SIJ variants (except for accessory joint) demonstrated 4 to 10 times higher odds for bone marrow edema, however not statistically significant. The more variants were present in this group, the higher the chance of bone marrow edema. However, some multicollinearity cannot be excluded, since bone marrow edema is very frequent in the axSpA group by definition. CONCLUSION SIJ variants are common in axSpA and non-SpA patients. SIJ variants were associated with higher prevalence of bone marrow edema in axSpA patients, potentially due to altered biomechanics, except for accessory joint which may act as a stabilizer.
Collapse
Affiliation(s)
- Elke Vereecke
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
| | - Lennart Jans
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Nele Herregods
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Min Chen
- Department of Radiology, Peking University Shenzhen Hospital, Shenzhen, China
| | - Jacob L Jaremko
- Department of Radiology and Diagnostic Imaging, Faculty of Medicine and Dentistry, University of Alberta Hospital, Edmonton, AB, Canada
| | - Frederiek Laloo
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Philippe Carron
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Gaëlle Varkas
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
- Department of Rheumatology, Jan Palfijn Hospital, Ghent, Belgium
| | - Manouk de Hooge
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Lieve Morbée
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| |
Collapse
|
5
|
de Hooge M, Ischenko A, Steinfeld S, Nzeusseu A, Elewaut D, Lories R, Van den Bosch F, De Vlam K. Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients. Ann Rheum Dis 2024; 83:194-198. [PMID: 37918893 PMCID: PMC10850634 DOI: 10.1136/ard-2023-224501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 10/02/2023] [Indexed: 11/04/2023]
Abstract
OBJECTIVES Investigating the association between different definitions of axial involvement and syndesmophytes development over 2 years in patients with psoriatic arthritis (PsA). METHODS Patients from a prospective multicentre cohort (Belgian Epidemiological Psoriatic Arthritis Study) involving 17 Belgian rheumatology practices were recruited between December 2012 and July 2014 and included when fulfilling the Classification Criteria for Psoriatic Arthritis. Axial involvement included six clinical and two radiographic oriented definitions.Two calibrated central readers evaluated radiographic damage by assessing the modified Stoke Ankylosing Spondylitis Spinal Score and modified New York criteria. New syndesmophytes after 2 years were described conditional on axial involvement at baseline. Logistic regression analyses were used to investigate the association between syndesmophyte development and axial involvement. All definitions of axial involvement were evaluated separately. RESULTS From 150 patients, a 2-year follow-up of spinal radiographs was obtained. There are 11 patients with new syndesmophytes after 2 years. For the clinical definitions of axial involvement 'global assessment', 'detailed assessment', 'back pain (BP)' and 'inflammatory BP (IBP)' the probabilities of developing syndesmophytes ranged between 0.06 and 0.08 and were similar for the presence or absence of the definition. When including elevated C reactive protein (CRP) to the definitions the probability of developing syndesmophytes over 2 years increased two times for CBP and seven times for IBP.With radiographic axial involvement a similar trend was seen; radiographic sacroiliitis as definition showed a probability three times higher. When combined with elevated CRP there would be a 14 times higher chance to develop syndesmophytes in 2 years. The ORs varied from 0.83 to 13.80, though none of them were statistically significant. CONCLUSIONS The likelihood of syndesmophyte formation in PsA is low. The probability of developing syndesmophytes is much higher when axial involvement is determined radiographically rather than clinically, particularly in the context of high CRP.
Collapse
Affiliation(s)
- Manouk de Hooge
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
- Rheumatology, University Hospital Gent, Gent, Belgium
| | - Alla Ischenko
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
| | - Serge Steinfeld
- Department of Rheumatology, Clinique St Jean, Brussels, Belgium
| | - Adrien Nzeusseu
- Department of Rheumatology, St Luc University Hospitals, Brussels, Belgium
| | - Dirk Elewaut
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
- Rheumatology, University Hospital Gent, Gent, Belgium
| | - Rik Lories
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
- Department of Development and Regeneration, Catholic University College Leuven Skeletal Biology and Engineering Research Center, Leuven, Belgium
| | - Filip Van den Bosch
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
- Rheumatology, Ghent University, Gent, Belgium
| | - Kurt De Vlam
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
- Department of Development and Regeneration, Catholic University College Leuven Skeletal Biology and Engineering Research Center, Leuven, Belgium
| |
Collapse
|
6
|
Roels J, De Craemer AS, Renson T, de Hooge M, Gevaert A, Van Den Berghe T, Jans L, Herregods N, Carron P, Van den Bosch F, Saeys Y, Elewaut D. Machine Learning Pipeline for Predicting Bone Marrow Edema Along the Sacroiliac Joints on Magnetic Resonance Imaging. Arthritis Rheumatol 2023; 75:2169-2177. [PMID: 37410803 DOI: 10.1002/art.42650] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 06/22/2023] [Accepted: 06/26/2023] [Indexed: 07/08/2023]
Abstract
OBJECTIVE We aimed to develop and validate a fully automated machine learning (ML) algorithm that predicts bone marrow edema (BME) on a quadrant level in sacroiliac (SI) joint magnetic resonance imaging (MRI). METHODS A computer vision workflow automatically locates the SI joints, segments regions of interest (ilium and sacrum), performs objective quadrant extraction, and predicts presence of BME, suggestive of inflammatory lesions, on a quadrant level in semicoronal slices of T1/T2-weighted MRI scans. Ground truth was determined by consensus among human readers. The inflammation classifier was trained using a ResNet18 backbone and five-fold cross-validated on scans of patients with spondyloarthritis (SpA) (n = 279), postpartum individuals (n = 71), and healthy subjects (n = 114). Independent SpA patient MRI scans (n = 243) served as test data set. Patient-level predictions were derived from aggregating quadrant-level predictions, ie, at least one positive quadrant. RESULTS The algorithm automatically detects the SI joints with a precision of 98.4% and segments ilium/sacrum with an intersection over union of 85.6% and 67.9%, respectively. The inflammation classifier performed well in cross-validation: area under the curve (AUC) 94.5%, balanced accuracy (B-ACC) 80.5%, and F1 score 64.1%. In the test data set, AUC was 88.2%, B-ACC 72.1%, and F1 score 50.8%. On a patient level, the model achieved a B-ACC of 81.6% and 81.4% in the cross-validation and test data set, respectively. CONCLUSION We propose a fully automated ML pipeline that enables objective and standardized evaluation of BME along the SI joints on MRI. This method has the potential to screen large numbers of patients with (suspected) SpA and is a step closer towards artificial intelligence-assisted diagnosis and follow-up.
Collapse
Affiliation(s)
- Joris Roels
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University, Ghent, Belgium
| | - Ann-Sophie De Craemer
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| | - Thomas Renson
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| | - Manouk de Hooge
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| | - Arne Gevaert
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University, Ghent, Belgium
| | | | | | | | - Philippe Carron
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| | - Filip Van den Bosch
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| | - Yvan Saeys
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University, Ghent, Belgium
| | - Dirk Elewaut
- Vlaams Instituut voor Biotechnologie - Universiteit Gent (VIB-UGent), Ghent-Zwijnaarde, and Ghent University Hospital, Ghent, Belgium
| |
Collapse
|
7
|
Mease P, Setty A, Papp K, Van den Bosch F, Tsuji S, Keiserman M, Carter K, Li Y, McCaskill R, McDearmon-Blondell E, Wung P, Tillett W. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol 2023; 41:2286-2297. [PMID: 37404160 DOI: 10.55563/clinexprheumatol/8l7bbk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 06/12/2023] [Indexed: 07/06/2023]
Abstract
OBJECTIVES To assess the long-term safety and efficacy of upadacitinib in patients with psoriatic arthritis (PsA) and an inadequate response (IR) to biologic disease-modifying anti-rheumatic drugs (bDMARDs) who completed up to 152 weeks of treatment in the SELECT-PsA 2 study (ClinicalTrials.gov: NCT03104374). METHODS Patients were randomised to receive blinded upadacitinib 15 or 30 mg once daily (QD), or placebo for 24 weeks followed by upadacitinib 15 or 30 mg QD. After 56 weeks, patients were eligible to enter an open-label extension (OLE) in which they continued their assigned dose of upadacitinib. Efficacy and safety were assessed through 152 weeks. A subanalysis of patients with IR to tumour necrosis factor inhibitors (TNFis) was also conducted. RESULTS In total, 450 patients entered the OLE and 358 completed 152 weeks of treatment. Improvements in efficacy outcomes observed at week 56, including the proportion of patients achieving: 20/50/70% improvement in American College of Rheumatology criteria, minimal disease activity, and 75/90/100% improvement in Psoriasis Area and Severity Index, were maintained through week 152. Efficacy outcomes in the TNFi-IR subgroup were similar to those reported in the overall population. Upadacitinib was well tolerated throughout long-term treatment, with no cumulative adverse effects observed through 152 weeks. CONCLUSIONS Efficacy of upadacitinib was maintained up to 152 weeks of treatment in this highly treatment-refractory population of patients with PsA. The long-term safety profile of upadacitinib 15 mg was consistent with its known safety profile across indications; no new safety signals were identified.
Collapse
Affiliation(s)
- Philip Mease
- Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, WA, USA.
| | | | - Kim Papp
- Alliance Clinical Trials and Probity Medical Research, Waterloo, ON, Canada
| | - Filip Van den Bosch
- Department of Internal Medicine and Paediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | - Shigeyoshi Tsuji
- Department of Orthopaedics, Rheumatology and Psoriasis Center, Nippon Life Hospital, Osaka, Japan
| | - Mauro Keiserman
- Rheumatology Section, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil
| | | | - Yihan Li
- AbbVie Inc, North Chicago, IL, USA
| | | | | | | | - William Tillett
- Department of Life Sciences, Centre for Therapeutic Innovation and Institute for Mathematical Innovation, University of Bath, UK
| |
Collapse
|
8
|
Mortier C, Quintelier K, De Craemer AS, Renson T, Deroo L, Dumas E, Verheugen E, Coudenys J, Decruy T, Lukasik Z, Van Gassen S, Saeys Y, Hoorens A, Lobatón T, Van den Bosch F, Van de Wiele T, Venken K, Elewaut D. Gut Inflammation in Axial Spondyloarthritis Patients is Characterized by a Marked Type 17 Skewed Mucosal Innate-like T Cell Signature. Arthritis Rheumatol 2023; 75:1969-1982. [PMID: 37293832 DOI: 10.1002/art.42627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 04/29/2023] [Accepted: 06/06/2023] [Indexed: 06/10/2023]
Abstract
OBJECTIVE Patients with spondyloarthritis (SpA) often present with microscopic signs of gut inflammation, a risk factor for progressive disease. We investigated whether mucosal innate-like T cells are involved in dysregulated interleukin-23 (IL-23)/IL-17 responses in the gut-joint axis in SpA. METHODS Ileal and colonic intraepithelial lymphocytes (IELs), lamina propria lymphocytes (LPLs), and paired peripheral blood mononuclear cells (PBMCs) were isolated from treatment-naive patients with nonradiographic axial SpA with (n = 11) and without (n = 14) microscopic gut inflammation and healthy controls (n = 15) undergoing ileocolonoscopy. The presence of gut inflammation was assessed histopathologically. Immunophenotyping of innate-like T cells and conventional T cells was performed using intracellular flow cytometry. Unsupervised clustering analysis was done by FlowSOM technology. Serum IL-17A levels were measured via Luminex. RESULTS Microscopic gut inflammation in nonradiographic axial SpA was characterized by increased ileal intraepithelial γδ-hi T cells, a γδ-T cell subset with elevated γδ-T cell receptor expression. γδ-hi T cells were also increased in PBMCs of patients with nonradiographic axial SpA versus healthy controls and were strongly associated with Ankylosing Spondylitis Disease Activity Score. The abundance of mucosal-associated invariant T cells and invariant natural killer T cells was unaltered. Innate-like T cells in the inflamed gut showed increased RORγt, IL-17A, and IL-22 levels with loss of T-bet, a signature that was less pronounced in conventional T cells. Presence of gut inflammation was associated with higher serum IL-17A levels. In patients treated with tumor necrosis factor blockade, the proportion of γδ-hi cells and RORγt expression in blood was completely restored. CONCLUSION Intestinal innate-like T cells display marked type 17 skewing in the inflamed gut mucosa of patients with nonradiographic axial SpA. γδ-hi T cells are linked to intestinal inflammation and disease activity in SpA.
Collapse
Affiliation(s)
- Céline Mortier
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Katrien Quintelier
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium, Data Mining and Modeling for Biomedicine group, VIB-UGent Center for Inflammation Research, Ghent, Belgium, and Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Ann-Sophie De Craemer
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Thomas Renson
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Liselotte Deroo
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Emilie Dumas
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Eveline Verheugen
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Julie Coudenys
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Tine Decruy
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Zuzanna Lukasik
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Sofie Van Gassen
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University and Data Mining and Modeling for Biomedicine group, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Yvan Saeys
- Department of Applied Mathematics, Computer Science and Statistics, Ghent University and Data Mining and Modeling for Biomedicine group, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Anne Hoorens
- Department of Pathology, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Triana Lobatón
- Department of Internal Medicine and Pediatrics, Ghent University and Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Tom Van de Wiele
- Center for Microbial Ecology and Technology, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium
| | - Koen Venken
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University and Unit for Molecular Immunology and Inflammation, VIB-UGent Center for Inflammation Research, Ghent, Belgium
| |
Collapse
|
9
|
Van Den Berghe T, Babin D, Chen M, Callens M, Brack D, Maes H, Lievens J, Lammens M, Van Sumere M, Morbée L, Hautekeete S, Schatteman S, Jacobs T, Thooft WJ, Herregods N, Huysse W, Jaremko JL, Lambert R, Maksymowych W, Laloo F, Baraliakos X, De Craemer AS, Carron P, Van den Bosch F, Elewaut D, Jans L. Neural network algorithm for detection of erosions and ankylosis on CT of the sacroiliac joints: multicentre development and validation of diagnostic accuracy. Eur Radiol 2023; 33:8310-8323. [PMID: 37219619 DOI: 10.1007/s00330-023-09704-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 03/03/2023] [Accepted: 03/25/2023] [Indexed: 05/24/2023]
Abstract
OBJECTIVES To evaluate the feasibility and diagnostic accuracy of a deep learning network for detection of structural lesions of sacroiliitis on multicentre pelvic CT scans. METHODS Pelvic CT scans of 145 patients (81 female, 121 Ghent University/24 Alberta University, 18-87 years old, mean 40 ± 13 years, 2005-2021) with a clinical suspicion of sacroiliitis were retrospectively included. After manual sacroiliac joint (SIJ) segmentation and structural lesion annotation, a U-Net for SIJ segmentation and two separate convolutional neural networks (CNN) for erosion and ankylosis detection were trained. In-training validation and tenfold validation testing (U-Net-n = 10 × 58; CNN-n = 10 × 29) on a test dataset were performed to assess performance on a slice-by-slice and patient level (dice coefficient/accuracy/sensitivity/specificity/positive and negative predictive value/ROC AUC). Patient-level optimisation was applied to increase the performance regarding predefined statistical metrics. Gradient-weighted class activation mapping (Grad-CAM++) heatmap explainability analysis highlighted image parts with statistically important regions for algorithmic decisions. RESULTS Regarding SIJ segmentation, a dice coefficient of 0.75 was obtained in the test dataset. For slice-by-slice structural lesion detection, a sensitivity/specificity/ROC AUC of 95%/89%/0.92 and 93%/91%/0.91 were obtained in the test dataset for erosion and ankylosis detection, respectively. For patient-level lesion detection after pipeline optimisation for predefined statistical metrics, a sensitivity/specificity of 95%/85% and 82%/97% were obtained for erosion and ankylosis detection, respectively. Grad-CAM++ explainability analysis highlighted cortical edges as focus for pipeline decisions. CONCLUSIONS An optimised deep learning pipeline, including an explainability analysis, detects structural lesions of sacroiliitis on pelvic CT scans with excellent statistical performance on a slice-by-slice and patient level. CLINICAL RELEVANCE STATEMENT An optimised deep learning pipeline, including a robust explainability analysis, detects structural lesions of sacroiliitis on pelvic CT scans with excellent statistical metrics on a slice-by-slice and patient level. KEY POINTS • Structural lesions of sacroiliitis can be detected automatically in pelvic CT scans. • Both automatic segmentation and disease detection yield excellent statistical outcome metrics. • The algorithm takes decisions based on cortical edges, rendering an explainable solution.
Collapse
Affiliation(s)
- Thomas Van Den Berghe
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
| | - Danilo Babin
- Department of Telecommunication and Information Processing - Image Processing and Interpretation (TELIN-IPI), Faculty of Engineering and Architecture, Ghent University - IMEC, Sint-Pietersnieuwstraat 41, 9000, Ghent, Belgium
| | - Min Chen
- Department of Radiology, Peking University Shenzhen Hospital, Shenzhen, 518036, China
| | - Martijn Callens
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Denim Brack
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Helena Maes
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Jan Lievens
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Marie Lammens
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Maxime Van Sumere
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Lieve Morbée
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Simon Hautekeete
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Stijn Schatteman
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Tom Jacobs
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Willem-Jan Thooft
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Nele Herregods
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Wouter Huysse
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Jacob L Jaremko
- Department of Radiology and Diagnostic Imaging and Rheumatology, University of Alberta, 8440 122 Street NW, Edmonton, Alberta, T6G 2B7, Canada
| | - Robert Lambert
- Department of Radiology and Diagnostic Imaging and Rheumatology, University of Alberta, 8440 122 Street NW, Edmonton, Alberta, T6G 2B7, Canada
| | - Walter Maksymowych
- Department of Radiology and Diagnostic Imaging and Rheumatology, University of Alberta, 8440 122 Street NW, Edmonton, Alberta, T6G 2B7, Canada
| | - Frederiek Laloo
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Xenofon Baraliakos
- Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Claudiusstraße 45, 44649, Herne, Germany
| | - Ann-Sophie De Craemer
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
- Vlaams Instituut voor Biotechnologie (VIB) Centre for Inflammation Research (IRC), Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Philippe Carron
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
- Vlaams Instituut voor Biotechnologie (VIB) Centre for Inflammation Research (IRC), Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
- Vlaams Instituut voor Biotechnologie (VIB) Centre for Inflammation Research (IRC), Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
- Vlaams Instituut voor Biotechnologie (VIB) Centre for Inflammation Research (IRC), Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Lennart Jans
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| |
Collapse
|
10
|
Scriffignano S, Lories R, Nzeusseu Toukap A, Lubrano E, Ciccia F, Steinfeld S, Perrotta FM, Pantano I, Van den Bosch F, de Vlam K. Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations. Clin Exp Rheumatol 2023; 41:1815-1822. [PMID: 36826796 DOI: 10.55563/clinexprheumatol/aovika] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Accepted: 01/09/2023] [Indexed: 02/25/2023]
Abstract
OBJECTIVES Psoriatic arthritis (PsA) is a chronic inflammatory disease, frequently associated with cardiovascular (CV) comorbidities. Our aim was to compare the prevalence of CV comorbidities between two groups of PsA patients from different European countries: Belgium and Italy. METHODS This is a cross-sectional analysis of two longitudinal cohorts in which 803 PsA patients were enrolled (463 from Belgium and 340 from Italy). All enrolled patients were ≥18 years old and fulfilled the ClASsification criteria for Psoriatic Arthritis (CASPAR criteria). For each patient, demographics, clinical assessments, smoking habits, the presence of arterial hypertension (AH), obesity (BMI ≥30), type 2 diabetes (T2D), CV diseases (acute myocardial infarction, stroke or transient ischaemic attack), dyslipidaemia (Italy only) and hypercholesterolaemia (Belgium only) were collected. RESULTS The most prevalent comorbidities among Italian patients with PsA were: AH (45.1%), dyslipidaemia (38.6%) and obesity (30.8%), and among Belgian patients were: hypercholesterolaemia (30.9%), obesity (27%) and AH (26.4%). Moreover, the prevalence of T2D and CV diseases was respectively 14.2% and 7.1% among Italian patients and 7.6% and 3.5% among Belgian patients. When comparing the two groups, AH, T2D and CV diseases were significantly more prevalent in Italian PsA patients. After controlling for different confounders, Italian patients, regardless of age, sex, smoking habits, PsA duration, other CV comorbidities, therapy, disease activity and function, had a higher risk to be hypertensive (OR 2.00, p=0.007). Instead of the country in which patients lived was not a predictor for the risk of T2D and CV diseases. Obesity prevalence was not different between the two groups. The lipid profile was unfavourable in both populations (even if not comparable between the two groups, due to the different way of collection), as is often the case in PsA. CONCLUSIONS The prevalence of AH, T2D and CV diseases were higher in Italian patients rather than Belgians. Moreover, among patients with PsA, the risk of AH was higher in the Italian cohort compared to the Belgian cohort. These results suggest that further research is needed to evaluate potential extrinsic factors (geography and sociocultural aspects) that may contribute to CV risk.
Collapse
Affiliation(s)
- Silvia Scriffignano
- Department of Rheumatology, UZ Leuven; Department Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Belgium, and Dipartimento di Medicina di Precisione, Section of Reumatology, Università degli Studi della Campania L. Vanvitelli, Naples, Italy
| | - Rik Lories
- Department of Rheumatology, UZ Leuven; and Department Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Belgium
| | - Adrien Nzeusseu Toukap
- Department of Rheumatology, IREC, UCLouvain and Cliniques Universitaires St. Luc, Brussels, Belgium
| | - Ennio Lubrano
- Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, Università degli Studi del Molise, Campobasso, Italy
| | - Francesco Ciccia
- Dipartimento di Medicina di Precisione, Section of Reumatology, Università degli Studi della Campania L. Vanvitelli, Naples, Italy
| | - Serge Steinfeld
- Department of Rheumatology, Hopitâl St Jean, Brussels, Belgium
| | - Fabio Massimo Perrotta
- Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute Vincenzo Tiberio, Università degli Studi del Molise, Campobasso, Italy
| | - Ilenia Pantano
- Dipartimento di Medicina di Precisione, Section of Reumatology, Università degli Studi della Campania L. Vanvitelli, Naples, Italy
| | - Filip Van den Bosch
- Department of Internal Medicine and Paediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | - Kurt de Vlam
- Department of Rheumatology, UZ Leuven; and Department Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Belgium.
| |
Collapse
|
11
|
Venken K, Jarlborg M, Decruy T, Mortier C, Vlieghe C, Gilis E, De Craemer AS, Coudenys J, Cambré I, Fleury D, Klimowicz A, Van den Bosch F, Hoorens A, Lobaton T, de Roock S, Sparwasser T, Nabozny G, Jacques P, Elewaut D. Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis. Ann Rheum Dis 2023; 82:1076-1090. [PMID: 37197892 DOI: 10.1136/ard-2022-223757] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 04/19/2023] [Indexed: 05/19/2023]
Abstract
OBJECTIVES Gut and joint inflammation commonly co-occur in spondyloarthritis (SpA) which strongly restricts therapeutic modalities. The immunobiology underlying differences between gut and joint immune regulation, however, is poorly understood. We therefore assessed the immunoregulatory role of CD4+FOXP3+ regulatory T (Treg) cells in a model of Crohn's-like ileitis and concomitant arthritis. METHODS RNA-sequencing and flow cytometry was performed on inflamed gut and joint samples and tissue-derived Tregs from tumour necrosis factor (TNF)∆ARE mice. In situ hybridisation of TNF and its receptors (TNFR) was applied to human SpA gut biopsies. Soluble TNFR (sTNFR) levels were measured in serum of mice and patients with SpA and controls. Treg function was explored by in vitro cocultures and in vivo by conditional Treg depletion. RESULTS Chronic TNF exposure induced several TNF superfamily (TNFSF) members (4-1BBL, TWEAK and TRAIL) in synovium and ileum in a site-specific manner. Elevated TNFR2 messenger RNA levels were noted in TNF∆ARE/+ mice leading to increased sTNFR2 release. Likewise, sTNFR2 levels were higher in patients with SpA with gut inflammation and distinct from inflammatory and healthy controls. Tregs accumulated at both gut and joints of TNF∆ARE mice, yet their TNFR2 expression and suppressive function was significantly lower in synovium versus ileum. In line herewith, synovial and intestinal Tregs displayed a distinct transcriptional profile with tissue-restricted TNFSF receptor and p38MAPK gene expression. CONCLUSIONS These data point to profound differences in immune-regulation between Crohn's ileitis and peripheral arthritis. Whereas Tregs control ileitis they fail to dampen joint inflammation. Synovial resident Tregs are particularly maladapted to chronic TNF exposure.
Collapse
Affiliation(s)
- Koen Venken
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Matthias Jarlborg
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Tine Decruy
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Céline Mortier
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Carolien Vlieghe
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Elisabeth Gilis
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Ann-Sophie De Craemer
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Julie Coudenys
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Isabelle Cambré
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Devan Fleury
- Immunology and Respiratory Department, Boehringer Ingelheim Corp Pharmaceutical Research and Development Centre Ridgefield, Ridgefield, Connecticut, USA
| | - Alexander Klimowicz
- Immunology and Respiratory Department, Boehringer Ingelheim Corp Pharmaceutical Research and Development Centre Ridgefield, Ridgefield, Connecticut, USA
| | - Filip Van den Bosch
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Anne Hoorens
- Department of Pathology, University Hospital Ghent, Gent, Belgium
| | - Triana Lobaton
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Gastroenterology unit), Ghent University, Ghent, Belgium
- Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
| | - Sytze de Roock
- Department of Pediatric Immunology, Center for Molecular and Cellular Intervention CMCI, Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Tim Sparwasser
- University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany
| | - Gerald Nabozny
- Immunology and Respiratory Department, Boehringer Ingelheim Corp Pharmaceutical Research and Development Centre Ridgefield, Ridgefield, Connecticut, USA
| | - Peggy Jacques
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| | - Dirk Elewaut
- Molecular Immunology and Inflammation Unit, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics (Rheumatology unit), Ghent University, Ghent, Belgium
| |
Collapse
|
12
|
Deroo L, Genbrugge E, Dochy F, Creytens D, Achten H, De Boeck K, Bauters W, Roels D, Deprez J, Van den Bosch F, Elewaut D, Peene I. Ultrasound-guided core needle biopsy and incisional biopsy of the parotid gland are comparable in diagnosis of primary Sjögren's syndrome. Rheumatology (Oxford) 2023; 62:2765-2772. [PMID: 36573316 DOI: 10.1093/rheumatology/keac714] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 12/02/2022] [Indexed: 08/03/2023] Open
Abstract
OBJECTIVES Salivary gland lymphocytic infiltrates are a hallmark of primary SS (pSS), but traditional biopsy techniques hold several disadvantages. Ultrasound-guided core needle (US-guided CN) parotid gland biopsy is minimally invasive and reliable for diagnosis of lymphoma in pSS. This proof-of-concept study aimed to explore this technique in the diagnostic work-up of pSS and is the first to address its value in a consecutive cohort independently of the presence of salivary gland swelling. METHODS Combined incisional and US-guided CN parotid biopsy was performed in 20 patients with suspected or confirmed pSS from the Belgian Sjögren's Syndrome Transition Trial (BeSSTT). Surface area and presence of a focus score (FS) of at least one, germinal centres and lymphoepithelial lesions were recorded. RESULTS Salivary gland tissue was interpretable in 19 patients. Fourteen patients had ≥4 mm2 salivary gland tissue by both techniques, in four US-guided CN biopsies salivary gland tissue was <4 mm2. Paired biopsies ≥4 mm2 displayed a concordance of 90% for FS ≥ 1. Presence of lymphoepithelial lesions and germinal centres showed absolute concordance. Of four US-guided CN biopsies <4 mm2, three interpretable incisional biopsies were available, 2/3 with perfect concordance. When including biopsies of <4 mm2 salivary gland tissue, presence of FS ≥ 1 or germinal centres gave a sensitivity of 70% in incisional and of 69% in US-guided CN biopsy. CONCLUSIONS US-guided CN biopsy of the parotid gland is at least equivalent to incisional biopsy of the parotid gland in the diagnostic work-up of pSS.
Collapse
Affiliation(s)
- Liselotte Deroo
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Universiteit Gent, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Eva Genbrugge
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - Frederick Dochy
- Department of Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium
| | - David Creytens
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Diagnostic Sciences, Universiteit Gent, Ghent, Belgium
| | - Helena Achten
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Universiteit Gent, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Kristel De Boeck
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Wouter Bauters
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - Dimitri Roels
- Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium
| | - Joke Deprez
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Universiteit Gent, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Universiteit Gent, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
| | - Isabelle Peene
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Pediatrics, Universiteit Gent, Ghent, Belgium
- Inflammation Research Center, VIB-UGent, Zwijnaarde, Belgium
- Department of Rheumatology, AZ Sint-Jan, Bruges, Belgium
| |
Collapse
|
13
|
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Lu W, Wang Z, Soliman AM, Eldred A, Padilla B, Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford) 2023; 62:2122-2129. [PMID: 36282537 PMCID: PMC10234194 DOI: 10.1093/rheumatology/keac605] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 10/15/2022] [Indexed: 09/30/2023] Open
Abstract
OBJECTIVE PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated. METHODS In the ongoing, phase 3, KEEPsAKE 2 trial, patients with active PsA were randomized 1:1 to receive subcutaneous risankizumab 150 mg or placebo at weeks 0, 4 and 16 (period 1). At week 24 (period 2), patients who received placebo were switched to risankizumab, and all patients received risankizumab 150 mg every 12 weeks from weeks 28 to 208. RESULTS At week 24, 51.3% of risankizumab-treated patients (n = 224) achieved ≥20% improvement in ACR criteria (ACR 20) vs 26.5% of placebo-treated patients (n = 220; P < 0.001). At week 52, 58.5% of patients randomized to receive continuous risankizumab achieved ACR20, and 55.7% of patients who switched from placebo to risankizumab at week 24 achieved ACR20. Similar trends were observed for other efficacy measures. Rates of serious treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation remained stable through week 52, and no deaths were reported. CONCLUSION Risankizumab was well tolerated and improved symptoms of PsA in Bio-IR/csDMARD-IR patients, with a consistent long-term safety profile from weeks 24 to 52. TRIAL REGISTRATION United States National Library of Medicine clinical trials database www.clinicaltrials.gov; KEEPsAKE 2; NCT03671148.
Collapse
Affiliation(s)
- Andrew Östör
- Department of Medicine, Monash University; Department of Rheumatology, Cabrini Hospital; and Emeritus Research, Melbourne, Victoria, Australia
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University, and Unit for Molecular Immunology and Inflammation, VIB Center for Inflammation Research, Ghent, Belgium
| | - Kim Papp
- Probity Medical Research–K. Papp Clinical Research, Waterloo, Ontario, Canada
| | | | - Ricardo Blanco
- Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Jacob Aelion
- Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, USA
| | | | | | | | | | | | - Alan Kivitz
- Altoona Center for Clinical Research, Duncansville, PA, USA
| |
Collapse
|
14
|
Braun J, Blanco R, Marzo-Ortega H, Gensler LS, Van den Bosch F, Hall S, Kameda H, Poddubnyy D, van de Sande M, van der Heijde D, Zhuang T, Stefanska A, Readie A, Richards HB, Deodhar A. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis. Arthritis Res Ther 2023; 25:80. [PMID: 37194094 DOI: 10.1186/s13075-023-03051-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/13/2023] [Indexed: 05/18/2023] Open
Abstract
BACKGROUND Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here. METHODS In the PREVENT study, adult patients fulfilling the Assessment of SpondyloArthritis International Society classification criteria for nr-axSpA with elevated CRP and/or MRI inflammation received secukinumab 150 mg or placebo. All patients received open-label secukinumab from week 52 onward. Sacroiliac (SI) joint and spinal radiographs were scored using the modified New York (mNY) grading (total sacroiliitis score; range, 0-8) and modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range, 0-72), respectively. SI joint bone marrow edema (BME) was assessed using the Berlin Active Inflammatory Lesions Scoring (0-24) and spinal MRI using the Berlin modification of the AS spine MRI (ASspiMRI) scoring (0-69). RESULTS Overall, 78.9% (438/555) of patients completed week 104 of the study. Over 2 years, minimal changes were observed in total radiographic SI joint scores (mean [SD] change, - 0.04 [0.49] and 0.04 [0.36]) and mSASSS scores (0.04 [0.47] and 0.07 [0.36]) in the secukinumab and placebo-secukinumab groups. Most of the patients showed no structural progression (increase ≤ smallest detectable change) in SI joint score (87.7% and 85.6%) and mSASSS score (97.5% and 97.1%) in the secukinumab and placebo-secukinumab groups. Only 3.3% (n = 7) and 2.9% (n = 3) of patients in the secukinumab and placebo-secukinumab groups, respectively, who were mNY-negative at baseline were scored as mNY-positive at week 104. Overall, 1.7% and 3.4% of patients with no syndesmophytes at baseline in the secukinumab and placebo-secukinumab group, respectively, developed ≥ 1 new syndesmophyte over 2 years. Reduction in SI joint BME observed at week 16 with secukinumab (mean [SD], - 1.23 [2.81] vs - 0.37 [1.90] with placebo) was sustained through week 104 (- 1.73 [3.49]). Spinal inflammation on MRI was low at baseline (mean score, 0.82 and 1.07 in the secukinumab and placebo groups, respectively) and remained low (mean score, 0.56 at week 104). CONCLUSION Structural damage was low at baseline and most patients showed no radiographic progression in SI joints and spine over 2 years in the secukinumab and placebo-secukinumab groups. Secukinumab reduced SI joint inflammation, which was sustained over 2 years. TRIAL REGISTRATION ClinicalTrials.gov, NCT02696031.
Collapse
Affiliation(s)
- Juergen Braun
- Department of Rheumatology, Ruhr-University Bochum, Bochum, Germany.
- Rheuma Praxis, Berlin, Germany.
| | - Ricardo Blanco
- Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Helena Marzo-Ortega
- NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, LIRMM, University of Leeds, Leeds, UK
| | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium
- VIB Center for Inflammation Research, Ghent, Belgium
| | - Stephen Hall
- Department of Medicine, Monash University, Melbourne, Australia
| | | | - Denis Poddubnyy
- German Rheumatism Research Centre, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Marleen van de Sande
- Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | | | | | | | - Aimee Readie
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | - Atul Deodhar
- Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Portland, USA
| |
Collapse
|
15
|
de Hooge M, Ishchenko A, De Craemer AS, Steinfeld S, Nzeusseu A, Elewaut D, Lories R, de Vlam K, Van den Bosch F. Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts. RMD Open 2023; 9:rmdopen-2023-002994. [PMID: 37137541 PMCID: PMC10163589 DOI: 10.1136/rmdopen-2023-002994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 04/02/2023] [Indexed: 05/05/2023] Open
Abstract
BACKGROUND To examine radiographic axial damage of the sacroiliac joints and spine in patients with psoriatic arthritis (PsA) and spondyloarthritis (SpA) in private and academic Belgian practices. METHODS Patients with PsA with clinical diagnosis of PsA and fulfilling the Classification Criteria for Psoriatic Arthritis from the prospective Belgian Epidemiological Psoriatic Arthritis Study and patients with SpA fulfilling the Assessment of SpondyloArthritis international Society classification criteria for SpA originate from the Ghent and BelGian Inflammatory Arthritis and spoNdylitis cohorTs were included in this study. Baseline pelvic and spinal radiographs were analysed by two calibrated readers. Blinded for the origin of the cohort or clinical data readers assessed the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and modified New York criteria on spinal and pelvic radiographs, respectively. Data were compared between both patient groups. RESULTS Of the 525 patients included (312 PsA and 213 SpA), most patients showed normal spinal radiographs: 87.5% of the patients with PsA and 92.0% of the patients with SpA. Patients with SpA with spinal damage show higher mSASSS than the patients with PsA (p<0.05). In patients with PsA, cervical spine is more often affected; 24/33 patients (72.7%) compared with lumbar spine 11/33 (33.3%). While in patients with SpA, syndesmophyte location was more evenly distributed; cervical 9/14 (64.3%) and lumbar 10/14 (71.4%). CONCLUSION Minimal radiographic spinal damage was observed in Belgian patients with PsA or SpA. Patients with SpA tend to have higher mSASSS values and more syndesmophytes compared with PsA. Syndesmophytes were more often located in the cervical spine of patients with PsA, while the location was equally distributed in axSpA.
Collapse
Affiliation(s)
- Manouk de Hooge
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Alla Ishchenko
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
| | - Ann-Sophie De Craemer
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Serge Steinfeld
- Department of Rheumatology, Clinique St Jean, Brussels, Belgium
| | - Adrien Nzeusseu
- Department of Rheumatology, St Luc University Hospitals, Brussels, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| | - Rik Lories
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
- Department of Development and Regeneration, Catholic University College Leuven Skeletal Biology and Engineering Research Center, Leuven, Belgium
| | - Kurt de Vlam
- Department of Rheumatology, KU Leuven university Hospital, Leuven, Belgium
- Department of Development and Regeneration, Catholic University College Leuven Skeletal Biology and Engineering Research Center, Leuven, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- Molecular Immunology and Inflammation Unit, VIB-UGent Center for Inflammation Research, Zwijnaarde, Belgium
| |
Collapse
|
16
|
van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis 2023; 82:515-526. [PMID: 36649967 PMCID: PMC10086273 DOI: 10.1136/ard-2022-223595] [Citation(s) in RCA: 14] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 12/26/2022] [Indexed: 01/19/2023]
Abstract
OBJECTIVES Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations, for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) and BE MOBILE 2 (radiographic axSpA (r-axSpA)) are double-blind, phase 3 trials designed to evaluate efficacy and safety of bimekizumab, a novel dual interleukin (IL)-17A and IL-17F inhibitor, across the axSpA spectrum. METHODS In parallel 52-week trials, patients with active disease were randomised 1:1 (nr-axSpA) or 2:1 (r-axSpA) to bimekizumab 160 mg every 4 weeks:placebo. From week 16, all patients received bimekizumab 160 mg every 4 weeks. Primary (Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40)) and secondary endpoints were assessed at week 16. Here, efficacy and treatment-emergent adverse events (TEAEs) are reported up to week 24. RESULTS 254 patients with nr-axSpA and 332 with r-axSpA were randomised. At week 16, primary (ASAS40, nr-axSpA: 47.7% bimekizumab vs 21.4% placebo; r-axSpA: 44.8% vs 22.5%; p<0.001) and all ranked secondary endpoints were met in both trials. ASAS40 responses were similar across TNFi-naïve and TNFi-inadequate responder patients. Improvements were observed in Ankylosing Spondylitis Disease Activity Score (ASDAS) states and objective measures of inflammation, including high-sensitivity C-reactive protein (hs-CRP) and MRI of the sacroiliac joints and spine. Most frequent TEAEs with bimekizumab (>3%) included nasopharyngitis, upper respiratory tract infection, pharyngitis, diarrhoea, headache and oral candidiasis. More fungal infections (all localised) were observed with bimekizumab vs placebo; no major adverse cardiovascular events (MACE) or active tuberculosis were reported. Incidence of uveitis and adjudicated inflammatory bowel disease was low. CONCLUSIONS Dual inhibition of IL-17A and IL-17F with bimekizumab resulted in significant and rapid improvements in efficacy outcomes vs placebo and was well tolerated in patients with nr-axSpA and r-axSpA.
Collapse
Affiliation(s)
| | - Atul Deodhar
- Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA
| | | | | | - Hiroaki Dobashi
- Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
| | - Maxime Dougados
- Department of Rheumatology, Hôpital Cochin, University Paris Cité, Paris, France
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
- VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | | | | | - Karl Gaffney
- Norfolk and Norwich University Hospital NHS Trust, Norfolk, UK
| | - Lianne S Gensler
- Department of Medicine/Rheumatology, University of California, San Francisco, California, USA
| | - Nigil Haroon
- University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, University of Toronto, Toronto, Ontario, Canada
| | - Marina Magrey
- University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA
| | | | | | | | | | - Denis Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | | | | | - Tetsuya Tomita
- Graduate School of Health Science, Morinomiya University of Medical Sciences, Osaka City, Osaka, Japan
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
| | | | - Huji Xu
- Affiliated to Second Military Medical University, Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Shanghai, China
| |
Collapse
|
17
|
De Craemer AS, Witte T, Lobaton Ortega T, Hoorens A, De Vos M, Cuvelier C, Vastert SJ, Baraliakos X, Van den Bosch F, Elewaut D. Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation. Rheumatology (Oxford) 2023; 62:984-990. [PMID: 35781486 DOI: 10.1093/rheumatology/keac384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 06/25/2022] [Accepted: 06/25/2022] [Indexed: 02/04/2023] Open
Abstract
OBJECTIVES Gut inflammation commonly occurs in axial SpA (axSpA), and is linked to disease activity and outcome. Given the role of IgA in mucosal immunity, we explored the association between anti-CD74 IgA antibodies, gut inflammation and axSpA. METHODS Anti-CD74 IgA was measured by ELISA in serum samples of axSpA patients, fulfilling the 2009 Assessment of SpondyloArthritis international Society classification criteria. A group of fibromyalgia (FM) and RA patients served as non-inflammatory and inflammatory controls. Newly diagnosed axSpA patients underwent ileocolonoscopy; mucosal biopsies were histopathologically assessed as normal, acute or chronically inflamed. Optimal anti-CD74 IgA cut-off values were determined with a receiver operating characteristics curve. RESULTS axSpA patients (n = 281) showed higher anti-CD74 IgA levels [mean (s.d.) 18.8 (12.4) U/ml] compared with 100 FM patients [10.9 (5.0) U/ml, P < 0.001] and 34 RA patients [13.7 (9.6) U/ml, P = 0.02]. The area under the receiver operating characteristics curve for diagnosis (axSpA vs FM) was 0.70, providing a sensitivity of 60% and specificity of 87% (cut-off 15 U/ml). Antibody concentrations were not significantly different between axSpA patients with (n = 40) and without (n = 69) gut inflammation (P = 0.83), yielding an area under the receiver operating characteristics curve of 0.51. Anti-CD74 IgA levels were not associated with degree of bone marrow oedema on MRI of the sacroiliac joints, CRP or any other disease-specific feature such as the use of NSAIDs or biological treatment. CONCLUSION Serum anti-CD74 IgA is a potentially useful diagnostic biomarker for axSpA. However, antibody levels do not correlate with any phenotypical feature, including microscopic gut inflammation, suggesting this to be a disease-specific rather than an inflammatory marker.
Collapse
Affiliation(s)
- Ann-Sophie De Craemer
- Department of Internal Medicine and Pediatrics, Ghent University
- Department of Rheumatology, Ghent University Hospital, Ghent
- Center for Inflammation Research, Molecular Immunology and Inflammation Unit, VIB-UGent, Zwijnaarde, Belgium
| | - Torsten Witte
- Department of Rheumatology and Clinical Immunology, Medical School Hannover, Hannover, Germany
| | - Triana Lobaton Ortega
- Department of Internal Medicine and Pediatrics, Ghent University
- Department of Gastroenterology
| | - Anne Hoorens
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - Martine De Vos
- Department of Internal Medicine and Pediatrics, Ghent University
- Department of Gastroenterology
| | - Claude Cuvelier
- Department of Pathology, Ghent University Hospital, Ghent, Belgium
| | - Sebastiaan J Vastert
- Department of Pediatric Rheumatology and Immunology, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, The Netherlands
| | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University
- Department of Rheumatology, Ghent University Hospital, Ghent
- Center for Inflammation Research, Molecular Immunology and Inflammation Unit, VIB-UGent, Zwijnaarde, Belgium
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Ghent University
- Department of Rheumatology, Ghent University Hospital, Ghent
- Center for Inflammation Research, Molecular Immunology and Inflammation Unit, VIB-UGent, Zwijnaarde, Belgium
| |
Collapse
|
18
|
Van den Bosch F, Wei JCC, Nash P, Blanco FJ, Graham D, Zang C, Arthur E, Borlenghi C, Tsekouras V, Vlahos B, Deodhar A. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial. J Rheumatol Suppl 2022; 50:478-487. [PMID: 36379575 DOI: 10.3899/jrheum.220353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2022] [Indexed: 11/16/2022]
Abstract
OBJECTIVE RE-EMBARK investigated etanercept (ETN) withdrawal and retreatment in patients with nonradiographic axial spondyloarthritis (nr-axSpA) achieving inactive disease. METHODS Patients received ETN and a background nonsteroidal antiinflammatory drug for 24 weeks in period 1 (P1); those achieving inactive disease (Ankylosing Spondylitis Disease Activity Score [ASDAS] with C-reactive protein [CRP] < 1.3) discontinued ETN for 40 weeks or less (period 2 [P2]). Patients who flared (ASDAS with erythrocyte sedimentation rate [ESR] ≥ 2.1) were retreated for 12 weeks in period 3 (P3). The primary endpoint was the proportion of patients with inactive disease who flared within 40 weeks of ETN withdrawal. Baseline characteristics were analyzed post hoc as predictors of maintenance and regaining of inactive disease, respectively, using univariate logistic and stepwise multivariable logistic regression models. RESULTS The proportion of patients experiencing flare following ETN withdrawal (P2) increased from 22.3% (25/112) after 4 weeks to 67% (77/115) after 40 weeks; 74.8% (86/115) experienced flare at any time during P2. Median time to flare was 16.1 weeks. Most patients (54/87, 62.1%) who were retreated with ETN in P3 reachieved inactive disease. Absence of both sacroiliitis detected on magnetic resonance imaging (MRI) and high-sensitivity CRP (hs-CRP) > 3 mg/L at baseline predicted inactive disease maintenance in P2 following ETN withdrawal in multivariable analysis; male sex and age younger than 40 years predicted regaining of inactive disease in P3 after flare/retreatment. There were no unexpected safety signals. CONCLUSION Approximately 25% of patients maintained inactive disease for 40 weeks after discontinuing ETN. Absence of both MRI sacroiliitis and high hs-CRP at baseline predicted response maintenance after ETN withdrawal. (ClinicalTrials.gov: NCT02509026).
Collapse
Affiliation(s)
- Filip Van den Bosch
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - James Cheng-Chung Wei
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Peter Nash
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Francisco J Blanco
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Daniela Graham
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Chuanbo Zang
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Edmund Arthur
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Cecilia Borlenghi
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Vassilis Tsekouras
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Bonnie Vlahos
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| | - Atul Deodhar
- This study was sponsored by Pfizer. F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, and VIB Center for Inflammation Research, Ghent, Belgium. J.C.C. Wei, MD, PhD, Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Institute of Medicine, College of Medicine, Chung Shan Medical University, and Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. P. Nash, MD, Department of Medicine, Griffith University, Brisbane, Australia. F.J. Blanco, MD, PhD, Universidad de A Coruña, Grupo de Investigación de Reumatología (GIR), INIBIC - Complejo Hospitalario Universitario de A Coruña, SERGAS, Departamento de Fisioterapia y Medicina, A Coruña, Spain. D. Graham, MD, Global Product Development, Pfizer, Groton, Connecticut, USA. C. Zang, PhD, Global Biometrics and Data Management, Pfizer, Collegeville, Pennsylvania, USA. E. Arthur, PharmD, Clinical Development and Operations, Pfizer, Peapack, New Jersey, USA. C. Borlenghi, MD, Inflammation & Immunology, Pfizer Global Medical Affairs, Buenos Aires, Argentina. V. Tsekouras, MD, PhD, Inflammation & Immunology, Pfizer Global Medical Affairs, Strovolos, Cyprus. B. Vlahos, BSN, MBA, Global Product Development, Pfizer, Collegeville, Pennsylvania, USA. A. Deodhar, MD, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA. FVdB reports grant/research support from AbbVie, Merck, and UCB; and consulting fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MoonLake, Novartis, Pfizer, and UCB. JCCW reports grant/ research support from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and consulting fees from TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma. PN reports grant/research support from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; reports consulting fees from AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis; and is on the speakers bureau for AbbVie, BMS, UCB, Lilly, Roche, Sanofi, Pfizer, Janssen, Gilead, and Novartis. FJB reports grant/ research support from Sanofi-Aventis, Lilly, BMS, Amgen, Pfizer, AbbVie, TRB Chemedica International, GSK, Archigen Biotech Limited, Novartis, Nichi-Iko Pharmaceutical, Genentech, Janssen Research & Development, UCB Biopharma, Centrexion Therapeutics, Celgene, Roche, Regeneron Pharmaceuticals, Biohope, Corbus Pharmaceutical, Tedec Meiji Pharma, Kiniksa Pharmaceuticals, and Gilead Sciences; and consulting fees from Lilly, BMS, Grunenthal, and Pfizer. DG, CZ, EA, CB, VT, and BV are employees of Pfizer and hold Pfizer stock. AD reports grant/research support from AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB; and consulting fees from Amgen, AbbVie, Aurinia, BI, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB. Address correspondence to Dr. F. Van den Bosch, Universitair Ziekenhuis Gent - Dienst Reumatologie (University Hospital Ghent - Department of Rheumatology), Corneel Heymanslaan 10, B-9000 Ghent, Belgium. . Accepted for publication November 9, 2022
| |
Collapse
|
19
|
Krabbe S, Renson T, Jans L, Elewaut D, Van den Bosch F, Carron P, Østergaard M. Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial. Rheumatology (Oxford) 2022:6749600. [PMID: 36200875 DOI: 10.1093/rheumatology/keac567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 08/25/2022] [Accepted: 09/26/2022] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES The aim was to investigate the reliability, validity, and sensitivity to change of a novel MRI scoring system in early peripheral SpA (pSpA). METHODS MRI of pelvis and lower extremities was performed before initiation of the TNF inhibitor golimumab in 56 patients and repeated in 46 patients who achieved sustained clinical remission after 24, 36 or 48 weeks. Three readers applied a semi-quantitative MRI scoring system for lower-extremity joint and entheseal inflammation. Four lesion types were assessed: entheseal osteitis, entheseal soft tissue inflammation, joint osteitis, and joint synovitis/effusion. MRI response was defined as a decrease in MRI lower-extremity inflammation index (sum of scores from 75 sites, each scored 0-3) above the smallest detectable change (SDC). RESULTS At follow-up, the MRI index decreased in 34 of 46 patients (74%), and fifteen (33%) patients achieved MRI response, i.e. a decrease above SDC of 2.8. When restricting the analysis to patients with clinical involvement of lower-extremity sites that were assessed by MRI, 13 of 28 (46%) achieved MRI response. Interreader reliability was very good with average-measure ICC of 0.92 (95% confidence interval: 0.85-0.95) for status scores and 0.89 (0.80-0.94) for change in scores. The MRI index correlated with other measures of disease activity, including C-reactive protein (Spearman's rho 0.41 (0.23-0.56)), swollen joint count of 6 joints (0.47 (0.27-0.63)), tender enthesis count of 14 entheses (0.32 (0.12-0.50)) and pain score (0.28 (0.08-0.46)), all p< 0.05. CONCLUSION The proposed MRI lower-extremity inflammation index demonstrated reliability, validity, and sensitivity to change in patients with early pSpA. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT01426815.
Collapse
Affiliation(s)
- Simon Krabbe
- Copenhagen Center for Arthritis Research, Center for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
| | - Thomas Renson
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Lennart Jans
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Philippe Carron
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Mikkel Østergaard
- Copenhagen Center for Arthritis Research, Center for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark.,Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
20
|
De Craemer AS, Deroo L, Renson T, Desimpele I, Delmez L, Decuman S, Janssens X, Boonen A, Elewaut D, Carron P, Van den Bosch F. Work participation is unaffected in Belgian spondyloarthritis patients: data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT. Rheumatology (Oxford) 2022; 62:1841-1850. [PMID: 36099046 DOI: 10.1093/rheumatology/keac529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2022] [Revised: 08/18/2022] [Accepted: 09/08/2022] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES This study aimed to (1) investigate actual work participation in Belgian spondyloarthritis (SpA) patients compared to the general population, and (2) identify determinants of work-related outcomes. METHODS Adult SpA patients from the Ghent University hospital based Be-GIANT cohort (fulfilling ASAS classification criteria) were cross-sectionally questioned on their socio-economic status and completed a Work Productivity and Activity Impairment questionnaire (May 2018 - May 2019). Results were compared to national and regional data on the general population using indirect standardization. Associations between clinical and job characteristics and work-related outcomes were analyzed with logistic regression (having a paid job) and negative binomial hurdle models (sick leave and presenteeism, i.e. restrictions while at work). RESULTS 215/262 (82%) patients of working-age (<65 y/o) had a paid job, corresponding to an age- and sex-adjusted employment ratio of 1.00 (95%CI 0.88;1.14). Patients worked 39.6±10.5h/week, and 49% (95%CI 42;56%) reported sick leave in the previous year, similar to the general population (39.7h/week, 42%). 56% reported presenteeism of median (IQR) 10% (0-20%). In multivariate analysis, functional impairment (BASFI) and health-related quality of life (HRQoL, EuroQoL-VAS) were associated with each work-related outcome, while contextual factors (education, physically demanding job) were positively associated with respectively having a paid job and presenteeism. Clinical characteristics showed no independent association with any of these outcomes. CONCLUSION Evidence from this academic cohort study does not support a work participation gap between SpA patients and the general population, but confirms the role of physical function, overall HRQoL, and education or job type as risk factors for adverse work outcomes.
Collapse
Affiliation(s)
- Ann-Sophie De Craemer
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| | - Liselotte Deroo
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| | - Thomas Renson
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| | - Ine Desimpele
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Lauren Delmez
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Saskia Decuman
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Service for benefits, National Institute for Health and Disability Insurance, Brussels, Belgium
| | - Xavier Janssens
- Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Annelies Boonen
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Dirk Elewaut
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| | - Philippe Carron
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, University Hospital Ghent, Ghent, Belgium.,Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.,Center for Inflammation Research, VIB-UGent, Zwijnaarde, Belgium
| |
Collapse
|
21
|
De Craemer AS, Renson T, Deroo L, Van Praet L, Cypers H, Varkas G, Joos R, Devinck M, Gyselbrecht L, Peene I, Thevissen K, Costantino F, D'Agostino MA, Lenaerts J, Carron P, Van den Bosch F, Elewaut D. Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis. Rheumatology (Oxford) 2022; 61:3279-3288. [PMID: 34850859 DOI: 10.1093/rheumatology/keab887] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 11/20/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES To delineate the impact of peripheral musculoskeletal manifestations on stratification of disease phenotype and outcome in new-onset spondyloarthritis (SpA), using a prospective observational nationwide inception cohort, the BelGian Inflammatory Arthritis and spoNdylitis cohorT (Be-Giant). METHODS Newly diagnosed adult SpA patients, fulfilling the Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral SpA, were included in Be-Giant and prospectively followed every six months. Peripheral involvement (defined as arthritis, enthesitis and/or dactylitis) was determined in relation to clinically similar patient subsets at baseline and disease activity patterns during two-year follow-up, identified through K-means cluster analysis and latent class growth analysis. RESULTS From November 2010 to March 2020, 367 patients were enrolled in Be-Giant, of whom 162 (44%) had peripheral manifestations. Two patient clusters [A, axial predominant (n = 248) and B, peripheral predominant (n = 119)] were identified at diagnosis. Longitudinal analysis (n = 115) revealed two trajectories of disease activity in each cluster: one with persistently high disease activity over time ('High'), the other rapidly evolving to low disease activity ('Low'). In cluster A patients, peripheral manifestations predisposed to the 'High' trajectory [odds ratio (OR) = 2.0, 95% CI: 1.3, 3.1, P = 0.001], despite more rapid initiation of biologics compared with patients without peripheral manifestations (hazard ratio (HR) = 2.1, 95% CI: 1.0, 4.4, P = 0.04 - Cox proportional-hazards model). CONCLUSION Peripheral musculoskeletal manifestations are major determinants of phenotypical diversity in new-onset SpA. Intriguingly, stratification of axial SpA according to concomitant peripheral involvement identified an endotype with an unfavorable outcome despite more prompt therapeutic intensification with biologics. These observations justify an endotype-tailored approach beyond current ASAS/EULAR management recommendations.
Collapse
Affiliation(s)
- Ann-Sophie De Craemer
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
| | - Thomas Renson
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
| | - Liselotte Deroo
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
| | | | | | - Gaëlle Varkas
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
| | - Rik Joos
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Department of Rheumatology, ZNA Jan Palfijn, Merksem
| | - Mieke Devinck
- Department of Rheumatology, AZ Sint-Lucas, Assebroek
| | - Lieve Gyselbrecht
- Department of Rheumatology, Algemeen Stedelijk Ziekenhuis (ASZ), Aalst
| | - Isabelle Peene
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Department of Rheumatology, AZ Sint-Jan, Brugge
| | - Kristof Thevissen
- Reumacentrum Genk, Genk
- Department of Rheumatology, Ziekenhuis Oost-Limburg (ZOL), Genk, Belgium
| | - Félicie Costantino
- Université Paris-Saclay, UVSQ, Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Montigny-Le-Bretonneux
- Rheumatology Department, AP-HP, Ambroise Paré Hospital, 92100, Boulogne-Billancourt, France
| | - Maria-Antonietta D'Agostino
- Université Paris-Saclay, UVSQ, Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Montigny-Le-Bretonneux
- Rheumatology Department, AP-HP, Ambroise Paré Hospital, 92100, Boulogne-Billancourt, France
- Rheumatology Department, Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy
| | - Jan Lenaerts
- Reuma Instituut
- Department of Rheumatology, AZ Jessa Hospitals, Hasselt
| | - Philippe Carron
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
- Department of Rheumatology, AZ Alma, Eeklo, Belgium
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, Gent
- Center for Inflammation Research, VIB-UGent, Zwijnaarde
| |
Collapse
|
22
|
Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022; 400:369-379. [PMID: 35908570 DOI: 10.1016/s0140-6736(22)01212-0] [Citation(s) in RCA: 45] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2022] [Revised: 06/15/2022] [Accepted: 06/21/2022] [Indexed: 12/11/2022]
Abstract
BACKGROUND Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis. METHODS The SELECT-AXIS 2 non-radiographic axial spondyloarthritis study was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 113 sites across 23 countries (Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Israel, Japan, Mexico, Poland, Russia, Slovakia, South Korea, Spain, Taiwan, Turkey, Ukraine, and the USA). Eligible adults had active non-radiographic axial spondyloarthritis, with objective signs of inflammation based on MRI or elevated C-reactive protein and an inadequate response to non-steroidal anti-inflammatory drugs. Patients were randomly assigned (1:1) to receive oral upadacitinib 15 mg once daily or placebo using interactive response technology. Random treatment assignment was stratified by MRI inflammation in the sacroiliac joints and screening high-sensitivity C-reactive protein status (MRI-positive and C-reactive protein-positive, MRI-positive and C-reactive protein-negative, and MRI-negative and C-reactive protein-positive) and previous exposure to biologic disease-modifying antirheumatic drugs (yes vs no). Treatment assignment was masked from patients, investigators, study site personnel, and the study sponsor. The primary endpoint was the proportion of patients with an Assessment of SpondyloArthritis international Society 40 (ASAS40) response at week 14. Analyses were performed on the full analysis set of patients, who underwent random allocation and received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04169373. FINDINGS Between Nov 26, 2019, and May 20, 2021, 314 patients with active non-radiographic axial spondyloarthritis were enrolled into the study, and 313 received study drug (156 in the upadacitinib group and 157 in the placebo group); 295 (94%) patients (145 in the upadacitinib group and 150 in the placebo group) received treatment for the full 14 weeks. A significantly higher ASAS40 response rate was achieved with upadacitinib compared with placebo at week 14 (70 [45%] of 156 patients vs 35 [23%] of 157 patients; p<0·0001; treatment difference 22%, 95% CI 12-32). The rate of adverse events up to week 14 was similar in the upadacitinib group (75 [48%] of 156 patients) and placebo group (72 [46%] of 157 patients). Serious adverse events and adverse events leading to discontinuation of study drug occurred in four (3%) of 156 patients in the upadacitinib group and two (1%) of 157 patients in the placebo group. Few patients had serious infections or herpes zoster in either treatment group (each event occurred in two [1%] of 156 patients in the upadacitinib group and one [1%] of 157 patients in the placebo group). Five (3%) of 156 patients in the upadacitinib group had neutropenia; no events of neutropenia occurred in the placebo group. No opportunistic infections, malignancies, major adverse cardiovascular events, venous thromboembolic events, or deaths were reported with upadacitinib treatment. INTERPRETATION Upadacitinib significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at week 14. These findings support the potential of upadacitinib as a new therapeutic option in patients with active non-radiographic axial spondyloarthritis. FUNDING AbbVie.
Collapse
Affiliation(s)
- Atul Deodhar
- Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA.
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | - Denis Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin, Berlin, Germany
| | | | | | - Tae-Hwan Kim
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
| | - Mitsumasa Kishimoto
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Ricardo Blanco
- Rheumatology Division, Hospital University Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Yuanyuan Duan
- Department of Immunology, AbbVie, North Chicago, IL, USA
| | - Yihan Li
- Department of Immunology, AbbVie, North Chicago, IL, USA
| | | | - Peter Wung
- Department of Immunology, AbbVie, North Chicago, IL, USA
| | - In-Ho Song
- Department of Immunology, AbbVie, North Chicago, IL, USA
| |
Collapse
|
23
|
van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, Van den Bosch F, Kim TH, Kishimoto M, Östör AJ, Combe B, Sui Y, Duan Y, Wung PK, Song IH. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD Open 2022; 8:rmdopen-2022-002280. [PMID: 35896281 PMCID: PMC9335045 DOI: 10.1136/rmdopen-2022-002280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 06/23/2022] [Indexed: 11/10/2022] Open
Abstract
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported. Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14 while patients initially randomised to upadacitinib continued their regimen through week 104. Efficacy was assessed using as-observed (AO) and non-responder imputation (NRI). Results Of 187 patients randomised, 144 patients (77%) completed week 104. Among patients receiving continuous upadacitinib, 85.9% (AO) and 65.6% (NRI) achieved Assessment of SpondyloArthritis international Society 40 response (ASAS40) at week 104. Similar magnitude of ASAS40 responses were observed among patients who switched from placebo to upadacitinib (88.7% and 63.8%, respectively). The mean change from baseline to week 104 in Spondyloarthritis Research Consortium of Canada MRI spine and sacroiliac joint inflammation scores were –7.3 and –5.3, respectively, in the continuous upadacitinib group and –7.9 and –4.9 in the placebo-to-upadacitinib switch group. The mean (95% CI) change from baseline to week 104 in the modified Stoke Ankylosing Spondylitis Spine Score was 0.7 (0.3, 1.1) in the total group. Adverse event rate was 242.7/100 patient-years. No serious infections, adjudicated major adverse cardiovascular events, lymphoma, non-melanoma skin cancer, or gastrointestinal perforations were observed. Conclusions Upadacitinib 15 mg once daily showed sustained and consistent efficacy over 2 years for ASAS40 and other clinically relevant endpoints. A low rate of radiographic progression was observed and no new safety findings were observed.
Collapse
Affiliation(s)
| | - Atul Deodhar
- Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA
| | | | - Joachim Sieper
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | - Tae-Hwan Kim
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
| | - Mitsumasa Kishimoto
- Department of Nephrology and Rheumatology, Kyorin University, School of Medicine, Tokyo, Japan
| | - Andrew J Östör
- Cabrini Medical Centre and Monash University, Melbourne, Victoria, Australia
| | - Bernard Combe
- Department of Rheumatology, Montpellier University, Montpellier, France
| | - Yunxia Sui
- AbbVie Inc, North Chicago, Illinois, USA
| | | | | | - In-Ho Song
- AbbVie Inc, North Chicago, Illinois, USA
| |
Collapse
|
24
|
Deroo L, Achten H, De Boeck K, Genbrugge E, Bauters W, Roels D, Dochy F, Creytens D, Deprez J, Van den Bosch F, Elewaut D, Peene I. The value of separate detection of anti-Ro52, anti-Ro60 and anti-SSB/La reactivities in relation to diagnosis and phenotypes in primary Sjögren's syndrome. Clin Exp Rheumatol 2022; 40:2310-1317. [DOI: 10.55563/clinexprheumatol/l70874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 08/26/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Liselotte Deroo
- Department of Rheumatology, Ghent University Hospital; Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent; and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Helena Achten
- Department of Rheumatology, Ghent University Hospital; Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent; and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Kristel De Boeck
- Department of Rheumatology, Ghent University Hospital, and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Eva Genbrugge
- Department of Radiology, Ghent University Hospital, Belgium
| | - Wouter Bauters
- Department of Radiology, Ghent University Hospital, Belgium
| | - Dimitri Roels
- Department of Ophthalmology, Ghent University Hospital, Belgium
| | - Frederick Dochy
- Department of Head and Neck Surgery, Ghent University Hospital, Belgium
| | - David Creytens
- Department of Pathology, Ghent University Hospital, and Faculty of Medicine and Health Sciences, Department of Diagnostic Sciences, Universiteit Gent, Belgium
| | - Joke Deprez
- Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent, and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital; Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent; and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital; Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent; and Centre for Inflammation Research, VIB-Ugent, Belgium
| | - Isabelle Peene
- Department of Rheumatology, Ghent University Hospital; Faculty of Medicine and Health Sciences, Department of Internal Medicine and Paediatrics, Universiteit Gent; Centre for Inflammation Research, VIB-Ugent, and Department of Rheumatology, AZ Sint-Jan, Bruges, Belgium.
| |
Collapse
|
25
|
Navarro-Compán V, Wei JCC, Van den Bosch F, Magrey M, Wang L, Fleishaker D, Cappelleri JC, Wang C, Wu J, Dina O, Fallon L, Strand V. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. RMD Open 2022; 8:rmdopen-2022-002253. [PMID: 35654457 PMCID: PMC9163535 DOI: 10.1136/rmdopen-2022-002253] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 03/31/2022] [Indexed: 11/08/2022] Open
Abstract
Background Ankylosing spondylitis (AS) impacts quality of life. We assessed patient-reported outcomes (PROs), pain, fatigue, health-related quality of life (HRQoL) and work productivity in a phase III trial of tofacitinib. Methods Adults with AS and with inadequate response/intolerance to ≥2 non-steroidal anti-inflammatory drugs received tofacitinib 5 mg twice daily or placebo for 16 weeks. Afterwards, all received open-label tofacitinib until week 48. Change from baseline to week 48 was determined for PROs: total back pain; nocturnal spinal pain; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) overall spinal pain (Q2); Functional Assessment of Chronic Illness Therapy-Fatigue; BASDAI fatigue (Q1); AS Quality of Life (ASQoL); Short Form-36 Health Survey Version 2 (SF-36v2); EuroQoL-Five Dimension-Three Level health profile and Visual Analogue Scale; and the Work Productivity and Activity Impairment (WPAI) questionnaire. Improvements from baseline ≥minimum clinically important difference, and scores ≥normative values at week 16 were evaluated. Results In 269 randomised and treated patients, at week 16, there were greater least squares mean improvements from baseline with tofacitinib 5 mg twice daily versus placebo in BASDAI overall spinal pain (–2.85 vs –1.34), BASDAI fatigue (–2.36 vs –1.08), ASQoL (–4.03 vs –2.01) and WPAI overall work impairment (–21.49 vs –7.64) (all p<0.001); improvements continued/increased to week 48. Improved spinal pain with tofacitinib was seen by week 2. Patients receiving tofacitinib reported clinically meaningful PRO improvements at week 16. Percentages with PRO scores ≥normative values at week 16 were greater with tofacitinib in SF-36v2 Physical Component Summary, physical functioning and bodily pain domains (p≤0.05). Conclusions In patients with AS, treatment with tofacitinib 5 mg twice daily resulted in clinically meaningful improvements in pain, fatigue, HRQoL and work productivity versus placebo to week 16, which were sustained to week 48. Trial registration number NCT03502616.
Collapse
Affiliation(s)
| | - James Cheng-Chung Wei
- Department of Allergy, Immunology & Rheumatology and Institute of Medicine, College of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.,Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent, Belgium
| | - Marina Magrey
- Case Western Reserve University School of Medicine, Division of Rheumatology, University Hospital of Cleveland, Cleveland, Ohio, USA
| | - Lisy Wang
- Pfizer Inc, Groton, Connecticut, USA
| | | | | | | | - Joseph Wu
- Pfizer Inc, Groton, Connecticut, USA
| | | | | | - Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA
| |
Collapse
|
26
|
Renson T, de Hooge M, De Craemer AS, Deroo L, Lukasik Z, Carron P, Herregods N, Jans L, Colman R, Van den Bosch F, Elewaut D. Progressive increase in sacroiliac joint and spinal mri lesions in healthy individuals in relation to age. Arthritis Rheumatol 2022; 74:1506-1514. [PMID: 35436391 DOI: 10.1002/art.42145] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 01/27/2022] [Accepted: 04/12/2022] [Indexed: 11/10/2022]
Abstract
OBJECTIVES MRI plays a pivotal role in spondyloarthritis (SpA) diagnosis. However, detailed description of MRI findings of the sacroiliac joints (SIJ) and spine in healthy individuals is currently lacking. We therefore sought to evaluate the occurrence of MRI-SIJ/spine lesions in healthy individuals in relation to age. METHODS Ninety-five healthy subjects (20-49 years) underwent MRI-SIJ and -spine. BME and structural lesions of the SIJ were scored using the SPARCC method. Spinal inflammatory and structural lesions were evaluated using the SPARCC MRI spine inflammation index and the CANDEN MRI scoring system, respectively. Fulfillment of the ASAS definition of a positive MRI for sacroiliitis/spondylitis was reviewed. Findings were compared with MRI of axial SpA patients from the Be-GIANT cohort. RESULTS 17.2% of subjects aged ≥30 fulfilled the definition of a positive MRI for sacroiliitis, but this occurred rarely in younger subjects. SIJ erosions (20.0%) and fat metaplasia (13.7%) were detected across all age groups. Erosions were more frequently visualized in subjects aged ≥40 (39.3%). Spinal BME (35.7%) and fat metaplasia (28.6%) were common in subjects older than 40 years. Nonetheless, only one subject had ≥3 corner inflammatory lesions. SIJ and spinal SPARCC scores and total structural lesions scores increased progressively with age. CONCLUSION Contrary to what is commonly believed, structural MRI-SIJ lesions are frequently seen in healthy individuals. Especially in older subjects, the high occurrence of inflammatory and structural MRI lesions impacts their specificity for SpA, which has important implications for the interpretation of MRI in patients with clinical suspicion of SpA.
Collapse
Affiliation(s)
- Thomas Renson
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Manouk de Hooge
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Ann-Sophie De Craemer
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Liselotte Deroo
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Zuzanna Lukasik
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Philippe Carron
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Nele Herregods
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - Lennart Jans
- Department of Radiology, Ghent University Hospital, Ghent, Belgium
| | - Roos Colman
- Department of Biostatistics, Ghent University, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium
| |
Collapse
|
27
|
Poddubnyy D, Baraliakos X, Van den Bosch F, Braun J, Coates LC, Chandran V, Diekhoff T, van Gaalen FA, Gensler LS, Goel N, Gottlieb AB, van der Heijde D, Helliwell PS, Hermann KGA, Jadon D, Lambert RG, Maksymowych WP, Mease P, Nash P, Proft F, Protopopov M, Sieper J, Torgutalp M, Gladman DD. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis 2022; 13:1759720X211057975. [PMID: 34987619 PMCID: PMC8721378 DOI: 10.1177/1759720x211057975] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 10/14/2021] [Indexed: 01/17/2023] Open
Abstract
Background: Involvement of the axial skeleton (sacroiliac joints and spine) is a relatively frequent manifestation associated with psoriatic skin disease, mostly along with involvement of peripheral musculoskeletal structures (peripheral arthritis, enthesitis, dactylitis), which are referred to as psoriatic arthritis (PsA). Data suggest that up to 30% of patients with psoriasis have PsA. Depending on the definition used, the prevalence of axial involvement varies from 25% to 70% of patients with PsA. However, there are currently no widely accepted criteria for axial involvement in PsA.Objective: The overarching aim of the Axial Involvement in Psoriatic Arthritis (AXIS) study is to systematically evaluate clinical and imaging manifestations indicative of axial involvement in patients with PsA and to develop classification criteria and a unified nomenclature for axial involvement in PsA that would allow defining a homogeneous subgroup of patients for research. Design: Prospective, multicenter, multinational, cross-sectional study. Methods and analyses: In this multicenter, multinational, cross-sectional study, eligible patients [adult patients diagnosed with PsA and fulfilling Classification Criteria for Psoriatic Arthritis (CASPAR) with musculoskeletal symptom duration of ⩽10 years not treated with biological or targeted synthetic disease-modifying anti-rheumatic drugs] will be recruited prospectively. They will undergo study-related clinical and imaging examinations. Imaging will include radiography and magnetic resonance imaging examinations of sacroiliac joints and spine. Local investigators will evaluate for the presence of axial involvement based on clinical and imaging information which will represent the primary outcome of the study. In addition, imaging will undergo evaluation by central review. Finally, the central clinical committee will determine the presence of axial involvement based on all available information. Ethics: The study will be performed according to the ethical principles of the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. The study protocol will be approved by the individual Independent Ethics Committee / Institutional Review Board of participating centers. Written informed consent will be obtained from all included patients.Registration: ClinicalTrials.gov ID: NCT04434885.
Collapse
Affiliation(s)
- Denis Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
| | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | - Jürgen Braun
- Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
| | - Laura C Coates
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - Vinod Chandran
- Division of Rheumatology, Department of Medicine, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
| | - Torsten Diekhoff
- Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Floris A van Gaalen
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
| | - Lianne S Gensler
- Division of Rheumatology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Niti Goel
- Patient Research Partner; Abcuro, Inc., Newton, MA, USA; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA
| | - Alice B Gottlieb
- Department of Dermatology, Mount Sinai-Beth Israel Hospital, Icahn School of Medicine, New York, NY, USA
| | | | - Philip S Helliwell
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK
| | - Kay Geert A Hermann
- Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Deepak Jadon
- Department of Medicine, University of Cambridge, Cambridge, UK
| | - Robert G Lambert
- Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada; Medical Imaging Consultants, Edmonton, AB, Canada
| | - Walter P Maksymowych
- Department of Medicine, University of Alberta, Edmonton, AB, Canada; CARE Arthritis, Edmonton, AB, Canada
| | - Philip Mease
- Division of Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, USA
| | - Peter Nash
- School of Medicine, Griffith University, Brisbane, QLD, Australia
| | - Fabian Proft
- Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Mikhail Protopopov
- Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Joachim Sieper
- Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Murat Torgutalp
- Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Dafna D Gladman
- Division of Rheumatology, Department of Medicine, University of Toronto, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
| |
Collapse
|
28
|
Costantino F, Aegerter P, Schett G, De Craemer AS, Molto A, Van den Bosch F, Elewaut D, Breban M, D'Agostino MA. Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations. Rheumatology (Oxford) 2021; 61:3289-3298. [PMID: 34864930 DOI: 10.1093/rheumatology/keab873] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 11/14/2021] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVES To assess whether two cluster analysis-based axial SpA (axSpA) endotypes (A for purely axial; B for both axial and peripheral) are stable over time and are associated with different long-term disease outcomes. METHODS K-means cluster analysis was performed at each visit (until 5 years) on 584 patients from the DESIR cohort, who completed all planned visits, and validated in 232 consecutive axSpA patients from the BeGiant cohort. Cluster stability overtime was assessed by kappa statistics. A generalized linear mixed-effect analysis was applied to compare outcomes between clusters. Classification and regression tree (CART) analysis was performed to determine a decision rule able to assign a given patient to a definite cluster at onset. RESULTS Both endotypes remained remarkably stable over time. In the DESIR cohort, patients in cluster B showed higher disease activity, worse functional outcome and higher need for anti-rheumatic drugs than patients in cluster A. CART analysis yielded three main clinical features (arthritis, enthesitis, and dactylitis) that accurately determined cluster assignment. These results could be replicated in the Be-GIANT cohort. CONCLUSION Cluster-based axSpA endotypes were reproducible in two different cohorts, stable over time and associated with different long-term outcome. The axSpA endotype with additional peripheral disease manifestations is associated with more severe disease and requires more intensive drug therapy. CLINICAL TRIAL REGISTRATION clinicaltrials.gov, https://clinicaltrials.gov, NCT01648907.
Collapse
Affiliation(s)
- Félicie Costantino
- Université Paris-Saclay, UVSQ, Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Montigny-Le-Bretonneux, 78180, France.,Rheumatology Department, AP-HP, Ambroise Paré Hospital, Boulogne-Billancourt, 92100, France
| | - Philippe Aegerter
- Université Paris-Saclay, UVSQ, Inserm U1018, CESP, Montigny-Le-Bretonneux, 78180, France.,GIRCI IdF-UFR Médecine Paris-Ile-de-France-Ouest Université, Boulogne-Billancourt, 92100, France
| | - Georg Schett
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen- Nuremberg and Universitatsklinikum Erlangen, Erlangen, 91054, Germany.,Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen- Nuremberg and Universitatsklinikum Erlangen, Erlangen, 91054, Germany
| | - Ann-Sophie De Craemer
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, C. Heymanslaan 10, Gent, 9000, Belgium.,Inflammation Research Center, VIB-UGent, Rijvisschestraat 152, Gent, 9052, Belgium
| | - Anna Molto
- Department of Clinical Epidemiology and Biostatistics, Université de Paris, Inserm U1153, Paris, 75000, France.,Rheumatology Department, AP-HP, Cochin Hospital, Paris, 75014, France
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, C. Heymanslaan 10, Gent, 9000, Belgium.,Inflammation Research Center, VIB-UGent, Rijvisschestraat 152, Gent, 9052, Belgium
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Division of Rheumatology, Ghent University Hospital, C. Heymanslaan 10, Gent, 9000, Belgium.,Inflammation Research Center, VIB-UGent, Rijvisschestraat 152, Gent, 9052, Belgium
| | - Maxime Breban
- Université Paris-Saclay, UVSQ, Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Montigny-Le-Bretonneux, 78180, France.,Rheumatology Department, AP-HP, Ambroise Paré Hospital, Boulogne-Billancourt, 92100, France
| | - Maria-Antonietta D'Agostino
- Université Paris-Saclay, UVSQ, Inserm U1173, Infection et inflammation, Laboratory of Excellence INFLAMEX, Montigny-Le-Bretonneux, 78180, France.,Rheumatology Department, AP-HP, Ambroise Paré Hospital, Boulogne-Billancourt, 92100, France.,Rheumatology Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy
| |
Collapse
|
29
|
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Alperovich G, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Kivitz A. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis 2021; 81:351-358. [PMID: 34815219 PMCID: PMC8862056 DOI: 10.1136/annrheumdis-2021-221048] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 10/12/2021] [Indexed: 01/20/2023]
Abstract
OBJECTIVES Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated the efficacy and safety of risankizumab versus placebo in patients with active PsA who had previous inadequate response or intolerance to ≤2 biological therapies (Bio-IR) and/or ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR). Results through week 24 are reported here. METHODS Adults with PsA who were Bio-IR and/or csDMARD-IR were randomised to receive subcutaneously administered risankizumab 150 mg or placebo at weeks 0, 4 and 16 during a 24-week, double-blind treatment period. The primary endpoint was the proportion of patients who achieved ≥20% improvement in American College of Rheumatology score (ACR20) at week 24. Secondary endpoints assessed key domains of PsA and patient-reported outcomes. RESULTS A total of 444 patients (median age 53 years, range 23-84 years) were randomised to risankizumab (n=224) or placebo (n=220); 206 patients (46.5%) were Bio-IR. At week 24, a significantly greater proportion of patients receiving risankizumab achieved the primary endpoint of ACR20 (51.3% vs 26.5%, p<0.001) and all secondary endpoints (p<0.05) compared with placebo. Serious adverse events were reported for 4.0% and 5.5% of risankizumab-treated and placebo-treated patients, respectively; serious infections were reported for 0.9% and 2.3%, respectively. CONCLUSION Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR. TRIAL REGISTRATION NUMBER NCT03671148.
Collapse
Affiliation(s)
- Andrew Östör
- Monash Medical School, Cabrini Hospital and Emertius Research, Melbourne, Victoria, Australia
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University, VIB Center for Inflammation Research, Gent, Belgium
| | - Kim Papp
- Probity Medical Research-K Papp Clinical Research, Waterloo, Ontario, Canada
| | | | - Ricardo Blanco
- Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Jacob Aelion
- Arthritis Clinic and West Tennessee Research Institute, Jackson, Tennessee, USA
| | | | | | | | | | | | | | - Alan Kivitz
- AbbVie Inc, North Chicago, Illinois, USA.,Altoona Center for Clinical Research, Pennsylvania, Duncansville, USA
| |
Collapse
|
30
|
Strand V, Van den Bosch F, Ranza R, Leung YY, Drescher E, Zueger P, Saffore CD, Lertratanakul A, Lippe R, Nash P. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatol Ther 2021; 8:1827-1844. [PMID: 34661885 PMCID: PMC8572272 DOI: 10.1007/s40744-021-00377-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 09/17/2021] [Indexed: 11/05/2022] Open
Abstract
Introduction Psoriatic arthritis (PsA) has a major impact on health-related quality of life (HRQOL) and other patient-reported outcomes (PROs), important components in the assessment of therapeutic efficacy. We evaluated the impact of upadacitinib on PROs in PsA patients with inadequate responses or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARD-IR). Methods Patients enrolled in the phase 3 SELECT-PsA 2 randomized controlled trial (RCT) received 56 weeks of oral upadacitinib 15 mg QD, upadacitinib 30 mg QD, or placebo switched to either dose of upadacitinib at week 24. PROs included patient global assessment of disease activity (PtGA), pain, physical function (HAQ-DI), health-related quality of life (SF-36 physical (PCS) and mental (MCS) component summary and domain scores), fatigue (FACIT-F), psoriasis symptom severity (SAPS), and work productivity (WPAI). Mean changes from baseline in PROs, improvements ≥ minimum clinically important differences (MCID) and scores ≥ normative values, and maintenance of improvements were assessed. Results At weeks 12 and 24, patients treated with either upadacitinib dose reported statistically and nominally significant improvements from baseline across all PROs versus placebo (p ≤ 0.05), except the WPAI absenteeism domain, which were maintained or further improved to week 56. A significantly greater proportion of patients receiving either upadacitinib dose reported improvements ≥ MCID and scores ≥ normative values versus placebo (nominal p ≤ 0.01) in most PROs at weeks 12 and 24, with clinically meaningful improvements continuing to week 56. Improvements ≥ MCID were reported as early as week 2 in PtGA, pain, and HAQ-DI. Conclusions Upadacitinib provides rapid, clinically meaningful, and sustained improvements in PROs reported by bDMARD-IR PsA patients. SELECT-PsA 2 ClinicalTrials.gov number, NCT03104374. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-021-00377-x.
Collapse
Affiliation(s)
- Vibeke Strand
- Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA
| | | | - Roberto Ranza
- Rheumatology Unit, Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil
| | - Ying-Ying Leung
- Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
| | - Edit Drescher
- Department of Rheumatology, Csolnoky Ferenc County Hospital/Vital Medical Center Private Clinic, Veszprém, Hungary
| | | | | | | | - Ralph Lippe
- AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
| | - Peter Nash
- Department of Medicine, Griffith University, Brisbane, QLD, Australia
| |
Collapse
|
31
|
Carron P, De Craemer AS, Renson T, Colman R, Elewaut D, Van den Bosch F. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate. Rheumatology (Oxford) 2021; 60:4880-4883. [PMID: 33471112 DOI: 10.1093/rheumatology/keab056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Accepted: 11/14/2020] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES Treatment with golimumab monotherapy in early peripheral SpA (pSpA) results in higher rates of clinical remission compared with treatment in more longstanding disease. When reaching remission, treat-to-target recommendations suggest tapering of treatment. We therefore explored whether addition of MTX would permit discontinuation of golimumab in patients with pSpA in sustained clinical remission. METHODS After a 2-year extension phase with golimumab treatment, patients with pSpA reaching clinical remission in the CRESPA trial were offered a tapering strategy leading to discontinuation of golimumab and replacement by MTX monotherapy. Patients were prospectively followed to assess the rate of sustained biologic-free clinical remission. In case of relapse of arthritis, enthesitis or dactylitis under MTX monotherapy, golimumab was restarted. RESULTS Of the original 60 pSpA patients, 25 entered the step-down strategy. Currently, only 4 patients (16%) are still in sustained remission under MTX monotherapy. In 21 patients (84%), golimumab was reinstalled because of relapse of disease activity (n = 19) or development of adverse events related to MTX (n = 2). Restarting golimumab treatment promptly restored clinical remission in all patients within 12 weeks. CONCLUSION In patients with early pSpA achieving clinical remission after 2 years of golimumab treatment, step-down therapy to monotherapy with MTX led to high rates of clinical relapse. This underscores the overall weak efficacy of MTX in maintaining clinical remission in pSpA. TRIAL REGISTRATION ClinicalTrials.gov, https://clinicaltrials.gov, NCT01426815.
Collapse
Affiliation(s)
- Philippe Carron
- Department of Internal Medicine and Paediatrics, Ghent University Hospital.,VIB Center for Inflammation Research
| | - Ann-Sophie De Craemer
- Department of Internal Medicine and Paediatrics, Ghent University Hospital.,VIB Center for Inflammation Research
| | - Thomas Renson
- Department of Internal Medicine and Paediatrics, Ghent University Hospital.,VIB Center for Inflammation Research
| | - Roos Colman
- Biostatistics Unit of the Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Dirk Elewaut
- Department of Internal Medicine and Paediatrics, Ghent University Hospital.,VIB Center for Inflammation Research
| | - Filip Van den Bosch
- Department of Internal Medicine and Paediatrics, Ghent University Hospital.,VIB Center for Inflammation Research
| |
Collapse
|
32
|
Kiltz U, Boonen A, van der Heijde D, Bautista-Molano W, Vargas RB, Chiowchanwisawakit P, El-Zorkany B, Gaydukova I, Geher P, Gossec L, Gilio M, Grazio S, Gu J, Khan MA, Kim TJ, Maksymowych WP, Marzo-Ortega H, Navarro-Compán V, Ozgocmen S, Patrikos D, Pimentel-Santos FM, Reveille J, Schirmer M, Stebbings S, Van den Bosch F, Weber U, Braun J. Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial Spondyloarthritis. Rheumatology (Oxford) 2021; 61:2054-2062. [PMID: 34534275 DOI: 10.1093/rheumatology/keab653] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 07/28/2021] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To describe the development of an Environmental contextual factors (EF) Item Set (EFIS) accompanying the disease specific Assessment of SpondyloArthritis international Society Health Index (ASAS HI). METHOD First, a candidate item pool was developed by linking items from existing questionnaires to 13 EF previously selected for the ICF/ASAS Core Set. Second, using data from two international surveys, which contained the EF item pool as well as the items from the ASAS HI, the number of EF-items was reduced based on the correlation between the item and the ASAS HI sum score combined with expert opinion. Third, the final English EFIS was translated into 15 languages and cross-culturally validated. RESULTS The initial item pool contained 53 EF addressing 4 ICF EF-chapters: products and technology (e1), support and relationship (e3), attitudes (e4) and health services (e5). Based on 1754 responses of axial spondyloarthritis patients in an international survey, 44 of 53 initial items were removed based on low correlations to the ASAS HI or redundancy combined with expert opinion. 9 items of the initial item pool (range correlation 0.21-0.49) form the final EFIS. The EFIS was translated into 15 languages and field tested in 24 countries. CONCLUSIONS An EFIS is available complementing the ASAS HI and helps to interpret the ASAS HI results by gaining an understanding of the interaction between a health condition and contextual factors. The EFIS emphasizes the importance of support and relationships, as well as attitudes of the patient and health services in relation to self-reported health.
Collapse
Affiliation(s)
- Uta Kiltz
- Rheumazentrum Ruhrgebiet, Herne Germany; and.,Ruhr-Universität Bochum, Germany
| | - Annelies Boonen
- Department of Internal MedicineDivision of Rheumatology, Maastricht University Medical Center, the Netherlands.,Care and Public Health Research Institute (CAPHRI), Maastricht University, the Netherlands
| | | | - Wilson Bautista-Molano
- University Hospital Fundación Santa Fe de Bogotá, and Universidad El Bosque, Bogotá, Colombia
| | | | | | | | | | - Pal Geher
- Semmelweis University, Budapest, Hungary
| | - Laure Gossec
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris France.,Pitié-Salpêtrière hospital, AP-HP Sorbonne Université, Rheumatology department, Paris, France
| | - Michele Gilio
- Department of Internal Medicine - "San Carlo" Hospital Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy
| | - Simeon Grazio
- Sestre milosrdnice University Hospital Center, Zagreb, Croatia
| | | | - Muhammad Asim Khan
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
| | - Tae-Jong Kim
- Chonnam National University Medical School and Hospital, Gwangju, South Korea
| | | | - Helena Marzo-Ortega
- NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
| | | | - Salih Ozgocmen
- Department of RheumatologyIstinye University, Medicalpark Gaziosmanpasa Hospital, Istanbul, Turkey
| | | | | | - John Reveille
- Department of Internal MedicineUniversity of Texas Health Science Center at Houston, USA
| | - Michael Schirmer
- Innsbruck Medical University, Department of Internal Medicine, Clinic IIAustria
| | - Simon Stebbings
- University of Otago, Dunedin School of Medicine, Dunedin, New Zealand
| | - Filip Van den Bosch
- VIB Center for Inflammation Research, Ghent, Belgium.,Department of Rheumatology Ghent University Hospital, Ghent, Belgium
| | - Ulrich Weber
- Practice Buchsbaum, Rheumatology, Schaffhausen, Switzerland
| | - Juergen Braun
- Rheumazentrum Ruhrgebiet, Herne Germany; and.,Ruhr-Universität Bochum, Germany
| |
Collapse
|
33
|
Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension. Arthritis Rheumatol 2021; 74:70-80. [PMID: 34196498 PMCID: PMC9299108 DOI: 10.1002/art.41911] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 06/29/2021] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To report efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS). METHODS In the SELECT-AXIS 1 study, adults with active AS and inadequate response to non-steroidal anti-inflammatory drugs were randomized to upadacitinib 15 mg once daily (QD) or placebo. At week 14, patients continued in the open-label extension and received upadacitinib up to week 104; reported here are interim data up to week 64. RESULTS Of 187 patients, 178 completed week 14 on study drug and entered the open-label extension. Similar proportions of patients in either group (continuous upadacitinib or placebo-to-upadacitinib) achieved Assessment of SpondyloArthritis international Society (ASAS) 40 or Ankylosing Spondylitis Disease Activity Score (ASDAS) low-disease activity at week 64: ≥70% of patients achieved these endpoints based on non-responder imputation (NRI) and ≥81% based on as-observed (AO) analyses. Furthermore, ≥34% (NRI) and ≥39% (AO) of patients achieved ASDAS inactive disease or ASAS partial remission at week 64. Mean changes from baseline (week 0) to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib (237.6 PY), 618 adverse events (260.1/100 PY) were reported. No serious infections, major adverse cardiovascular events, venous thromboembolic events, gastrointestinal perforation, or deaths were reported. CONCLUSION Upadacitinib 15 mg QD showed sustained and consistent efficacy over 1 year. Patients who switched from placebo to upadacitinib at week 14 showed similar efficacy versus those who received continuous upadacitinib.
Collapse
Affiliation(s)
- Atul Deodhar
- Oregon Health & Science University, Portland, OR, United States
| | | | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium
| | | | - Tae-Hwan Kim
- Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
| | | | - Andrew Ostor
- Cabrini Medical Center, Monash University, Melbourne, VIC, Australia
| | - Bernard Combe
- CHU Montpellier, Montpellier University, Montpellier, France
| | - Yunxia Sui
- AbbVie Inc, North Chicago, IL, United States
| | | | - In-Ho Song
- AbbVie Inc, North Chicago, IL, United States
| |
Collapse
|
34
|
Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD. Axial involvement in psoriatic arthritis: An update for rheumatologists. Semin Arthritis Rheum 2021; 51:880-887. [PMID: 34198146 DOI: 10.1016/j.semarthrit.2021.06.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2021] [Revised: 06/09/2021] [Accepted: 06/15/2021] [Indexed: 02/08/2023]
Abstract
Psoriatic arthritis (PsA) is a heterogenous, chronic, inflammatory musculoskeletal disease that can lead to peripheral and axial damage and loss of function. Axial involvement occurs in 25% to 70% of patients with PsA, varying greatly depending on its definition, with the key manifestations being sacroiliitis and/or spondylitis. However, there are no agreed-upon classification or diagnostic criteria for axial involvement in PsA and no consensus on treatment paradigms, which complicates management of PsA. There have only been a few studies assessing biologics in patients with PsA with axial involvement, and most treatment plans are based on evidence from patients with axial spondyloarthritis. Rheumatologists therefore face many challenges in the management of axial PsA, including diagnosis, differential diagnosis, and choice of appropriate treatment. In this review, we summarize the clinical presentation, imaging characteristics, differential diagnoses, treatment options, and prognosis of axial PsA, with the aim of increasing rheumatologists' knowledge of this phenotype of PsA and thereby aiding its optimal management.
Collapse
Affiliation(s)
- Denis Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
| | - Deepak R Jadon
- Department of Rheumatology, University of Cambridge, Cambridge, United Kingdom
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, and VIB Center for Inflammation Research, Ghent, Belgium
| | - Philip J Mease
- Swedish Medical Center/Providence St Joseph Health, Seattle, WA, USA, and University of Washington, Seattle, WA, USA
| | - Dafna D Gladman
- Schroeder Arthritis Institute, Krembil Research Institutef, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
| |
Collapse
|
35
|
Renson T, Carron P, De Craemer AS, Deroo L, de Hooge M, Krabbe S, Jans L, Østergaard M, Elewaut D, Van den Bosch F. The value of magnetic resonance imaging for assessing disease extent and prediction of relapse in early peripheral spondyloarthritis. Arthritis Rheumatol 2021; 73:2044-2051. [PMID: 33982902 DOI: 10.1002/art.41783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 03/24/2021] [Accepted: 04/22/2021] [Indexed: 11/07/2022]
Abstract
OBJECTIVE We aimed to assess the inflammatory burden in pSpA by lower-extremity MRI in an early remission-induction strategy study with TNF blockade. Furthermore, we sought to determine the value of MRI to predict disease relapse versus sustained remission after treatment discontinuation. METHODS Thirty-two early pSpA patients with lower limb involvement on clinical examination and confirmed by ultrasonography, participated in a remission-induction trial with a TNF-inhibitor (TNFi). Patients underwent MRI of joints and entheses of the lower extremities at baseline and at clinical remission, after which TNFi treatment was withdrawn. Images were evaluated for joint effusion, joint osteitis, entheseal soft tissue inflammation (STI), and entheseal osteitis. RESULTS Joint effusion and enthesitis on clinical examination and ultrasonography correlated well with MRI abnormalities. In addition, a substantial amount of subclinical involvement was seen on MRI, mainly in ankle joints and heel entheses. Inflammation scores were markedly lower in the subclinical joints and entheses versus those clinically involved. Inflammatory load on MRI decreased significantly upon TNFi treatment. Whereas 80% of the clinically involved joints at baseline showed no effusion on remission MRI, two out of three involved entheses at baseline showed residual inflammation. In addition, patients relapsing after treatment discontinuation displayed more entheseal STI on remission MRI compared to those maintaining drug-free remission. CONCLUSION Our findings delineate a differential response of synovitis and enthesitis, with enthesitis on MRI responding less upon TNFi treatment. Furthermore, residual entheseal inflammation might be indicative for the need for continuous therapy.
Collapse
Affiliation(s)
- Thomas Renson
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Philippe Carron
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Ann-Sophie De Craemer
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Liselotte Deroo
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Manouk de Hooge
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Simon Krabbe
- Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 1-23, 2600, Denmark.,Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Nørregade 10, 1017, Copenhagen, Denmark
| | - Lennart Jans
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Mikkel Østergaard
- Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Valdemar Hansens Vej 1-23, 2600, Denmark.,Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Nørregade 10, 1017, Copenhagen, Denmark
| | - Dirk Elewaut
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent University, Technologiepark-Zwijnaarde 71, 9052, Ghent, Belgium
| |
Collapse
|
36
|
Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis 2021; 80:1022-1030. [PMID: 33958326 PMCID: PMC8292566 DOI: 10.1136/annrheumdis-2020-219717] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Revised: 02/12/2021] [Accepted: 03/05/2021] [Indexed: 12/23/2022]
Abstract
Objectives The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission. Methods COAST-Y is an ongoing, phase III, long-term extension study that included a double-blind, placebo (PBO)-controlled, randomised withdrawal-retreatment period (RWRP). Patients who completed the originating 52-week COAST-V, COAST-W or COAST-X studies entered a 24-week lead-in period and continued either 80 mg IXE every 2 (Q2W) or 4 weeks (Q4W). Patients who achieved remission (an Ankylosing Spondylitis Disease Activity Score (ASDAS)<1.3 at least once at week 16 or week 20, and <2.1 at both visits) were randomly assigned equally at week 24 to continue IXE Q4W, IXE Q2W or withdraw to PBO in a blinded fashion. The primary endpoint was the proportion of flare-free patients (flare: ASDAS≥2.1 at two consecutive visits or ASDAS>3.5 at any visit) after the 40-week RWRP, with time-to-flare as a major secondary endpoint. Results Of 773 enrolled patients, 741 completed the 24-week lead-in period and 155 entered the RWRP. Forty weeks after randomised withdrawal, 83.3% of patients in the combined IXE (85/102, p<0.001), IXE Q4W (40/48, p=0.003) and IXE Q2W (45/54, p=0.001) groups remained flare-free versus 54.7% in the PBO group (29/53). Continuing IXE significantly delayed time-to-flare versus PBO, with most patients remaining flare-free for up to 20 weeks after IXE withdrawal. Conclusions Patients with axSpA who continued treatment with IXE were significantly less likely to flare and had significantly delayed time-to-flare compared with patients who withdrew to PBO.
Collapse
Affiliation(s)
- Robert Bm Landewé
- Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands
| | - Lianne S Gensler
- Department of Medicine, University of California San Francisco, San Francisco, California, USA
| | - Denis Poddubnyy
- Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Proton Rahman
- Department of Rheumatology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada
| | - Maja Hojnik
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Xiaoqi Li
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | | | - David Adams
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.,VIB Center for Inflammation Research, Ghent, Belgium
| | | |
Collapse
|
37
|
Schett G, Baraliakos X, Van den Bosch F, Deodhar A, Østergaard M, Gupta AD, Mpofu S, Fox T, Winseck A, Porter B, Shete A, Gensler LS. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies. J Rheumatol 2021; 48:1251-1258. [PMID: 33722947 DOI: 10.3899/jrheum.201111] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/26/2021] [Indexed: 12/17/2022]
Abstract
OBJECTIVE To assess the efficacy of secukinumab on axial and peripheral enthesitis in patients with ankylosing spondylitis (AS) using pooled data from randomized controlled phase III studies. METHODS In this posthoc analysis, data were pooled from patients originally randomized to secukinumab 150 mg, 300 mg, or placebo (PBO) from phase III MEASURE 1-4 studies (ClinicalTrials.gov: NCT01358175, NCT01649375, NCT02008916, and NCT02159053). Maastricht AS Enthesitis Score (MASES) was used for assessments of enthesitis through Week 52. Efficacy outcomes were mean change in MASES score and complete resolution (MASES = 0) of enthesitis in patients with baseline MASES > 0. RESULTS A total of 693 (71.5%) patients had enthesitis at baseline in secukinumab 300 mg, 150 mg, and PBO groups (58 [76.3%], 355 [70.4%], and 280 [72%], respectively) out of 969 patients pooled in this analysis. At Week 16, mean changes from baseline for overall MASES and enthesitis at axial MASES sites, respectively, were as follows: -2.9 (P < 0.01) and -2.9 (P < 0.01) for secukinumab 300 mg; -2.4 (P < 0.015) and -2.3 (P < 0.05) for secukinumab 150 mg; and -1.9 and -1.8 for PBO, with improvements seen through Week 52. More than one-third of secukinumab-treated patients (300 mg: 36.2%; 150 mg: 40.8%) achieved complete resolution of enthesitis at Week 16. CONCLUSION Secukinumab improved enthesitis at overall MASES and axial sites in patients with AS.
Collapse
Affiliation(s)
- Georg Schett
- G. Schett, MD, Department of Internal Medicine, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany;
| | - Xenofon Baraliakos
- X. Baraliakos, MD, Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Germany
| | - Filip Van den Bosch
- F. Van den Bosch, MD, PhD, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, and VIB Center for Inflammation Research, Ghent, Belgium
| | - Atul Deodhar
- A. Deodhar, MD, Oregon Health & Science University, Portland, Oregon, USA
| | - Mikkel Østergaard
- M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
| | - Ayan Das Gupta
- A. Das Gupta, PhD, Novartis Healthcare Pvt. Ltd., Hyderabad, India
| | - Shephard Mpofu
- S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland
| | - Todd Fox
- S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland
| | - Adam Winseck
- A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Brian Porter
- A. Winseck, PhD, B. Porter, MD, PhD, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Abhijit Shete
- S. Mpofu, MD, T. Fox, RPh, PharmB, ACPR, A. Shete, MD, Novartis Pharma AG, Basel, Switzerland
| | - Lianne S Gensler
- L.S. Gensler, MD, University of California, San Francisco, University of California, California, USA
| |
Collapse
|
38
|
Jans LBO, Chen M, Elewaut D, Van den Bosch F, Carron P, Jacques P, Wittoek R, Jaremko JL, Herregods N. MRI-based Synthetic CT in the Detection of Structural Lesions in Patients with Suspected Sacroiliitis: Comparison with MRI. Radiology 2020; 298:343-349. [PMID: 33350891 DOI: 10.1148/radiol.2020201537] [Citation(s) in RCA: 74] [Impact Index Per Article: 18.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Background Evaluation of structural lesions in the sacroiliac (SI) joints can improve the accuracy for diagnosis of spondyloarthritis. However, structural lesions, such as erosions, are difficult to assess on routine T1-weighted MRI scans. Purpose To determine the diagnostic performance of MRI-based synthetic CT (sCT) in the depiction of erosions, sclerosis, and ankylosis of the SI joints compared with T1-weighted MRI, with CT as the reference standard. Materials and Methods A prospective study (clinical trial registration no. B670201837885) was performed from February 2019 to November 2019. Adults were referred from a tertiary hospital rheumatology outpatient clinic with clinical suspicion of inflammatory sacroiliitis. MRI and CT of the SI joints were performed on the same day. SCT images were generated from MRI scans using a commercially available deep learning-based image synthesis method. Two readers independently recorded if structural lesions (erosions, sclerosis, and ankylosis) were present on T1-weighted MRI, sCT, and CT scans in different reading sessions, with readers blinded to clinical information and other images. Diagnostic performance of sCT and T1-weighted MRI scans were analyzed using generalized estimating equation models, with consensus results of CT as the reference standard. Results Thirty participants were included (16 men, 14 women; mean age, 40 years ± 10 [standard deviation]). Diagnostic accuracy of sCT was higher than that of T1-weighted MRI for erosion (94% vs 86%, P = .003), sclerosis (97% vs 81%, P < .001), and ankylosis (92% vs 84%, P = .04). With sCT, specificity for erosion detection (96% [95% CI: 90, 98] vs 89% [95% CI: 81, 94], P = .01] and sensitivity for detection of sclerosis [94% [95% CI: 87, 97] vs 20% [95% CI: 10, 35], P < .001] and ankylosis (93% [95% CI: 78, 98] vs 70% [95% CI: 47, 87], P = .001) were improved. Conclusion With CT as the reference standard, synthetic CT of the sacroiliac joints has better diagnostic performance in the detection of structural lesions in individuals suspected of having sacroiliitis compared with routine T1-weighted MRI. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Fritz in this issue.
Collapse
Affiliation(s)
- Lennart B O Jans
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Min Chen
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Dirk Elewaut
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Filip Van den Bosch
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Philippe Carron
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Peggy Jacques
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Ruth Wittoek
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Jacob L Jaremko
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| | - Nele Herregods
- From the Departments of Radiology (L.B.O.J., M.C., N.H.) and Rheumatology (D.E., F.V.d.B., P.C., P.J., R.W.), Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium; VIB Center for Inflammation Research, Unit for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium (D.E., F.v.d.B., P.C., P.J., R.W.); and Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, Edmonton, Canada (J.L.J.)
| |
Collapse
|
39
|
Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, Dokoupilova E, Keiserman M, Wang X, Zhong S, McCaskill RM, Zueger P, Pangan AL, Tillett W. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020; 80:312-320. [PMID: 33272960 PMCID: PMC7892371 DOI: 10.1136/annrheumdis-2020-218870] [Citation(s) in RCA: 108] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 09/22/2020] [Accepted: 10/12/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). METHODS In this 24-week randomised, placebo-controlled, double-blind, phase 3 trial, 642 patients were randomised (2:2:1:1) to once per day upadacitinib 15 mg or 30 mg, placebo followed by upadacitinib 15 mg or placebo followed by upadacitinib 30 mg at week 24. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 12. Achievement of minimal disease activity (MDA) was assessed at week 24. Treatment-emergent adverse events are reported for all patients who received at least one dose of trial drug. RESULTS At week 12, significantly more patients receiving upadacitinib 15 mg and 30 mg versus placebo achieved ACR20 (56.9% and 63.8% vs 24.1%; p<0.001 for both comparisons). At week 24, MDA was achieved by more upadacitinib 15 mg-treated (25.1%) and 30 mg-treated patients (28.9%) versus placebo (2.8%; p<0.001 for both comparisons). Generally, the rates of treatment-emergent adverse events were similar with placebo and upadacitinib 15 mg and higher with upadacitinib 30 mg at week 24. Rates of serious infections were 0.5%, 0.5% and 2.8% with placebo, upadacitinib 15 mg and upadacitinib 30 mg, respectively. CONCLUSION In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of PsA. CLINICAL TRIAL REGISTRATION NUMBER NCT03104374.
Collapse
Affiliation(s)
- Philip J Mease
- Rheumatology, Swedish Medical Center, Seattle, Washington, USA .,School of Medicine, University of Washington, Seattle, Washington, USA
| | | | | | - Kim Papp
- Probity Medical Research and K Papp Clinical Research Inc, Waterloo, Ontario, Canada
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University, VIB Center for Inflammation Research, Ghent, Belgium, Gent, Belgium
| | - Shigeyoshi Tsuji
- Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Kawachi-Nagano, Japan
| | - Eva Dokoupilova
- Medical Plus, Uherske Hradiste, Czech Republic.,Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Jihomoravský, Czech Republic
| | - Mauro Keiserman
- Rheumatology Section, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil
| | - Xin Wang
- AbbVie Inc, North Chicago, Illinois, USA
| | | | | | | | | | - William Tillett
- Department of Rheumatology, Royal National Hospital for Rheumatic Disease, Bath, UK.,Department of Pharmacy and Pharmacology, Centre for Therapeutic Innovation and Institute for Mathematical Innovation, University of Bath, Bath, UK
| |
Collapse
|
40
|
Landewé R, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch F, Gaffney K, Bauer L, Hoepken B, de Peyrecave N, Thomas K, Gensler LS. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. Rheumatol Ther 2020; 7:581-599. [PMID: 32529495 PMCID: PMC7410911 DOI: 10.1007/s40744-020-00214-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Indexed: 01/15/2023] Open
Abstract
INTRODUCTION Achievement of remission is a key treatment goal for patients with axial spondyloarthritis (axSpA). C-OPTIMISE assessed achievement of sustained clinical remission in patients with axSpA, including radiographic (r) and non-radiographic (nr) axSpA, during certolizumab pegol (CZP) treatment, and subsequent maintenance of remission following CZP dose continuation, dose reduction or withdrawal. Here, we report outcomes from the first 48 weeks (induction period) of C-OPTIMISE, during which patients received open-label CZP. METHODS C-OPTIMISE (NCT02505542) was a two-part, multicenter, phase 3b study in adult patients with early axSpA (r-/nr-axSpA), including a 48-week open-label induction period followed by a 48-week maintenance period. Patients with active adult-onset axSpA, < 5 years' symptom duration, and fulfilling Assessment of SpondyloArthritis international Society classification criteria, were included. During the induction period, patients received a loading dose of CZP 400 mg at weeks 0, 2, and 4, followed by CZP 200 mg every 2 weeks (Q2W) up to week 48. The main outcome of the 48-week induction period was the achievement of sustained clinical remission (defined as an Ankylosing Spondylitis Disease Activity Score [ASDAS] < 1.3 at week 32 and < 2.1 at week 36 [or vice versa], and < 1.3 at week 48). RESULTS In total, 736 patients (407 with r-axSpA, 329 with nr-axSpA) were enrolled into the study. At week 48, 43.9% (323/736) of patients achieved sustained remission, including 42.8% (174/407) of patients with r-axSpA and 45.3% (149/329) with nr-axSpA. Patients also demonstrated substantial improvements in axSpA symptoms, MRI outcomes and quality of life measures. Adverse events occurred in 67.9% (500/736) of patients, of which 6.0% (44/736) were serious. CONCLUSIONS Over 40% of patients with early axSpA achieved sustained remission during 48 weeks of open-label CZP treatment. Additionally, patients across the axSpA spectrum demonstrated substantial improvements in imaging outcomes and quality of life following treatment. No new safety signals were identified. TRIAL REGISTRATION NCT02505542.
Collapse
Affiliation(s)
- Robert Landewé
- Amsterdam Rheumatology and Clinical Immunology Center, Amsterdam, The Netherlands.
- Zuyderland Medical Center, Heerlen, The Netherlands.
| | | | - Maxime Dougados
- Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
- INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
| | | | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Karl Gaffney
- Rheumatology Department, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK
| | | | | | | | | | | |
Collapse
|
41
|
Carron P, De Craemer AS, Van den Bosch F. Peripheral spondyloarthritis: a neglected entity-state of the art. RMD Open 2020; 6:e001136. [PMID: 32385142 PMCID: PMC7299516 DOI: 10.1136/rmdopen-2019-001136] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 04/06/2020] [Accepted: 04/07/2020] [Indexed: 02/06/2023] Open
Abstract
Peripheral spondyloarthritis (pSpA) refers to a number of seemingly different spondyloarthritis subsets in which psoriatic arthritis (PsA) is the most common, and symptoms of arthritis, enthesitis or dactylitis predominate the clinical presentation. Although formal classification criteria for pSpA have been introduced in 2011, only a minority of epidemiological and clinical studies addressed this clinical entity as a separate disease. Moreover, research on outcome measures and treatment modalities in pSpA has been mainly focused on PsA. Subsequently, all biological treatments are off-label in patients with non-psoriatic pSpA. Its neglected status has important implications for clinical practice since the emerging group of early-diagnosed non-psoriatic pSpA patients remains poorly characterised and lacks specific treatment recommendations. This review summarises what is currently known regarding pSpA in terms of epidemiology, clinical presentation, diagnosis and therapeutic approach.
Collapse
Affiliation(s)
- Philippe Carron
- Rheumatology, University Hospital Ghent, Ghent, Belgium
- VIB Center for Inflammation Research, Ghent, Belgium
| | - Ann-Sophie De Craemer
- Rheumatology, University Hospital Ghent, Ghent, Belgium
- VIB Center for Inflammation Research, Ghent, Belgium
| | - Filip Van den Bosch
- Rheumatology, University Hospital Ghent, Ghent, Belgium
- VIB Center for Inflammation Research, Ghent, Belgium
| |
Collapse
|
42
|
Coates L, Mease P, Gladman D, den Bosch FV, Rychlewska-Hanczewska A, Tasset C, Meuleners L, Trivedi M, Guo Y, Besuyen R, Helliwell P. P219 Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. Rheumatology (Oxford) 2020. [DOI: 10.1093/rheumatology/keaa111.214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Filgotinib (FIL) is an orally administered, selective janus kinase 1 (JAK1) inhibitor in development for psoriatic arthritis (PsA). Efficacy and safety of FIL in patients with active PsA were evaluated in a 16-week phase 2 study (EQUATOR, NCT03101670). After 16 weeks, patients could roll-over to an Open Label Extension (OLE) Study (EQUATOR2, NCT03320876) for the purpose of evaluating long-term safety and efficacy. The aim of this analysis was to assess safety and efficacy through 52 weeks of exposure to filgotinib.
Methods
Patients who completed the randomised, double-blind, placebo-controlled study were eligible for participation in the OLE, during which all patients received once daily (qd) open-label FIL 200mg. In this interim analysis of OLE, for the safety analysis, all data were included from the screening in the core study up to the data cut of 18 April 2019 in the OLE. For the efficacy analysis, all data until OLE Week 52 visit for each patient were included (observed case analysis).
Results
Of the 131 patients randomised and dosed in EQUATOR, 124 (95%) completed the study and 122 (93%) enrolled in EQUATOR2; 50% were female and mean age was 50. At this interim analysis, 106/122 (87%) remained in the OLE (premature discontinuations during OLE due to: 4 for safety, 11 withdrew consent, and 1 for other reasons). Cumulative patient years of exposure (PYE) on FIL were 160, median time on FIL was 66 weeks. Key safety data are summarised in Table 1. Key ≥Grade 2 treatment-emergent laboratory abnormalities seen with FIL arm (N = 128) compared with PBO (N = 66) were lymphocyte decrease 11.1% vs 4.5%, neutrophil decrease 5.5% vs 0%, ALT increase 1.6% vs 1.5% and creatinine increase 0.8% vs 0%, respectively. At week 52, 34% of the patients fulfilled criteria for minimal disease activity and 81%, 55%, and 33% of patients, respectively, achieved ACR20/50/70 responses.
Conclusion
FIL 200mg qd was generally well tolerated and the safety profile in PsA was comparable to that observed in the FIL rheumatoid arthritis studies. The data from this interim analysis suggest that further improvement of the patient condition can be expected beyond 16 weeks of treatment.
Disclosures
L. Coates: Other; Received support from Abbvie, Amgen, Celgene, Galapagos, Janssen, Lilly, Novartis, Pfizer, Prothena, Sun pharma, and UCB. P. Mease: Other; Received support from Abbvie, Amgen, BMS, Celgene, Galapagos, Genentech, Gilead, Janssen, Eli Lilly, Merck, Novartis, Pfizer, SUN, and UCB. D. Gladman: Other; Received support from Abbvie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, UCB, BMS, and Galapagos. F. Van den Bosch: Other; Received support from Abbvie, Bristol-Myers Squibb, Eli Lilly, Galapagos, Janssen, Merck, Novartis, Pfizer, and UCB. A. Rychlewska-Hanczewska: Other; Received support from Galapagos and Gilead Sciences. C. Tasset: Corporate appointments; Employee of Galapagos NV. L. Meuleners: Corporate appointments; Employee of Galapagos NV. M. Trivedi: Corporate appointments; Employee of Gilead Sciences, Inc. Shareholder/stock ownership; Shareholder of Gilead Sciences, Inc. Y. Guo: Corporate appointments; Employee of Gilead Sciences, Inc... Shareholder/stock ownership; Shareholder of Gilead Sciences, Inc. R. Besuyen: Other; Employee of Galapagos NV. P. Helliwell: Other; Received support from Abbvie, Amgen, Celgene, Galapagos, Janssen, Novartis, Pfizer, and UCB.
Collapse
Affiliation(s)
- Laura Coates
- Rheumatology, University of Oxford, Oxford, UNITED KINGDOM
| | - Philip Mease
- Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA
| | - Dafna Gladman
- Rheumatology, University of Toronto, Toronto, ON, CANADA
| | | | | | | | | | | | - Ying Guo
- Rheumatology, Gilead Sciences, Foster City, CA
| | | | - Philip Helliwell
- Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UNITED KINGDOM
| |
Collapse
|
43
|
Chen M, Herregods N, Jaremko JL, Carron P, Elewaut D, Van den Bosch F, Jans L. Bone marrow edema in sacroiliitis: detection with dual-energy CT. Eur Radiol 2020; 30:3393-3400. [PMID: 32055947 DOI: 10.1007/s00330-020-06670-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 12/30/2019] [Accepted: 01/23/2020] [Indexed: 12/23/2022]
Abstract
OBJECTIVES To evaluate the feasibility and diagnostic accuracy of dual-energy computed tomography (DECT) for the detection of bone marrow edema (BME) in patients suspected for sacroiliitis. METHODS Patients aged 18-55 years with clinical suspicion for sacroiliitis were enrolled. All patients underwent DECT and 3.0 T MRI of the sacroiliac joints on the same day. Virtual non-calcium (VNCa) images were calculated from DECT images for demonstration of BME. VNCa images were scored by two readers independently using a binary system (0 = normal bone marrow, 1 = BME). Diagnostic performance was assessed with fluid-sensitive MRI as the reference standard. ROIs were placed on VNCa images, and CT numbers were displayed. Cutoff values for BME detection were determined based on ROC curves. RESULTS Forty patients (16 men, 24 women, mean age 37.1 years ± 9.6 years) were included. Overall inter-reader agreement for visual image reading of BME on VNCa images was good (κ = 0.70). The sensitivity and specificity of BME detection by DECT were 65.4% and 94.2% on the quadrant level and 81.3% and 91.7% on the patient level. ROC analyses revealed AUCs of 0.90 and 0.87 for CT numbers in the ilium and sacrum, respectively. Cutoff values of - 44.4 HU (for iliac quadrants) and - 40.8 HU (for sacral quadrants) yielded sensitivities of 76.9% and 76.7% and specificities of 91.5% and 87.5%, respectively. CONCLUSIONS Inflammatory sacroiliac BME can be detected by VNCa images calculated from DECT, with a good interobserver agreement, moderate sensitivity, and high specificity. KEY POINTS • Virtual non-calcium images calculated from dual-energy CT can detect sacroiliac bone marrow edema in patients suspected for sacroiliitis. • Dual-energy CT has a high specificity in bone marrow edema detection. • Virtual non-calcium images for bone marrow edema in patients with a large amount of red bone marrow or obvious sclerosis near the articular surface should be interpreted with caution.
Collapse
Affiliation(s)
- Min Chen
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
| | - Nele Herregods
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Jacob L Jaremko
- Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, 8440-112 Street, Edmonton, Alberta, T6G 2B7, Canada
| | - Philippe Carron
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Lennart Jans
- Department of Radiology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| |
Collapse
|
44
|
Varkas G, Ribbens C, Louis E, Van den Bosch F, Lories R, Vermeire S, Elewaut D, De Vos M. Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies. Aliment Pharmacol Ther 2019; 50:1204-1213. [PMID: 31650573 DOI: 10.1111/apt.15519] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 01/13/2019] [Accepted: 09/08/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Spondyloarthritis is the most frequent extra-intestinal manifestation of IBD. AIM To present simple strategies to identify and differentiate inflammatory joint pain in IBD patients. METHODS A panel of Belgian gastroenterologists and rheumatologists developed seven algorithms for IBD patients with joint symptoms based on a Delphi exercise conducted between April and December 2016. Here, we focus on referral strategies for patients with chronic back pain (evidence-based strategy), large joint monoarthritis, oligo- or polyarticular arthritis or arthralgia (based on expert opinion). We also present management tools for IBD patients with acute back pain and small joint monoarthritis (Supplementary file). RESULTS The reported algorithm for IBD patients with chronic back pain uses basic clinical criteria to identify which patients should be referred to the emergency room (spondylodiscitis), physical medicine and rehabilitation (mechanical back pain) or rheumatologist (spondyloarthritis). IBD patients with large joint monoarthritis should be referred to emergency room if septic arthritis is suspected; in other patients, blood analyses and referral to a rheumatologist for articular puncture with evacuation of synovial fluid are recommended. The analysis of synovial fluid allows for identification of non-inflammatory (e.g., osteoarthritis) and inflammatory (e.g., [pseudo]-gout, peripheral spondyloarthritis and Borrelia burgdorferi arthritis) conditions. In patients with inflammatory oligoarticular or polyarticular arthralgia, erythrocyte sedimentation rate, concomitant therapies, anti-nuclear factor and anti-double-stranded DNA antibody levels should be evaluated; in anti-tumour necrosis factor-treated patients, a drug-induced lupus-like syndrome should be considered. CONCLUSION We propose straightforward strategies for IBD patients with joint symptoms, which are specific enough to select initial treatment and referral pattern.
Collapse
Affiliation(s)
- Gaëlle Varkas
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Clio Ribbens
- Department of Rheumatology, University of Liège, Liège, Belgium
| | - Edouard Louis
- Department of Hepato-Gastroenterology, CHU Liège, University of Liège, Liège, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Rik Lories
- Laboratory of Tissue Homeostasis and Disease, Division of Rheumatology, Skeletal Biology and Engineering Research Center, University Hospitals Leuven, Leuven, Belgium
| | - Séverine Vermeire
- Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), University Hospitals Leuven, Leuven, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Martine De Vos
- Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium
| |
Collapse
|
45
|
Dougados M, Wei JCC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 2019; 79:176-185. [PMID: 31685553 PMCID: PMC7025731 DOI: 10.1136/annrheumdis-2019-216118] [Citation(s) in RCA: 65] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 10/03/2019] [Accepted: 10/05/2019] [Indexed: 12/17/2022]
Abstract
OBJECTIVES To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W). METHODS Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W (ADA) in COAST-V and 1:1:1 (n=316) to IXE Q2W, IXE Q4W or PBO in COAST-W. At week 16, patients receiving ixekizumab continued their assigned treatment; patients receiving PBO or ADA were rerandomised 1:1 to IXE Q2W or IXE Q4W (PBO/IXE, ADA/IXE) through week 52. RESULTS In COAST-V, Assessment of SpondyloArthritis international Society 40 (ASAS40) responses rates (intent-to-treat population, non-responder imputation) at weeks 16 and 52 were 48% and 53% (IXE Q4W); 52% and 51% (IXE Q2W); 36% and 51% (ADA/IXE); 19% and 47% (PBO/IXE). Corresponding ASAS40 response rates in COAST-W were 25% and 34% (IXE Q4W); 31% and 31% (IXE Q2W); 14% and 39% (PBO/IXE). Both ixekizumab regimens sustained improvements in disease activity, physical function, objective markers of inflammation, QoL, health status and overall function up to 52 weeks. Safety through 52 weeks of ixekizumab was consistent with safety through 16 weeks. CONCLUSION The significant efficacy demonstrated with ixekizumab at week 16 was sustained for up to 52 weeks in bDMARD-naive and TNFi-experienced patients. bDMARD-naive patients initially treated with ADA demonstrated further numerical improvements after switching to ixekizumab. Safety findings were consistent with the known safety profile of ixekizumab. TRIAL REGISTRATION NUMBER NCT02696785/NCT02696798.
Collapse
Affiliation(s)
- Maxime Dougados
- Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique - Hôpitaux de Paris; INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France
| | - James Cheng-Chung Wei
- Institute of Medicine, Chung Shan Medical University; Department of Internal Medicine, Chung Shan Medical University Hospital; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan
| | - Robert Landewé
- Amsterdam Rheumatology and Clinical Immunology Center, Amsterdam, The Netherlands
| | | | | | | | | | - Joerg Ermann
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Jessica A Walsh
- Division of Rheumatology, University of Utah and Salt Lake City Veterans Affairs Medical Centers, Salt Lake City, Utah, USA
| | - Tetsuya Tomita
- Department of Orthopaedic Biomaterial Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Atul Deodhar
- Oregon Health and Science University, Portland, Oregon, USA
| | | | - Xiaoqi Li
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | - Fangyi Zhao
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | | | - Gaia Gallo
- Eli Lilly and Company, Indianapolis, Indiana, USA
| | | | | | | |
Collapse
|
46
|
Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 2019; 5:e001005. [PMID: 31565244 PMCID: PMC6744073 DOI: 10.1136/rmdopen-2019-001005] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 07/26/2019] [Accepted: 08/18/2019] [Indexed: 12/17/2022] Open
Abstract
Objective This study aimed to report end-of-study results on efficacy and safety of secukinumab 150 mg through 5 years in patients with ankylosing spondylitis (AS; MEASURE 1 extension trial (NCT01863732)). Methods After the 2-year core trial, 274 patients receiving subcutaneous secukinumab 150 or 75 mg (following intravenous loading or initial placebo treatment to 16/24 weeks) every 4 weeks were invited to enter the 3-year extension study. Dose escalation from 75 to 150 mg (approved dose) was allowed at or after week 156 based on the judgement of the treating physician. Assessments at week 260 (5 years) included Assessment of SpondyloArthritis international Society (ASAS) 20/40 and other efficacy outcomes. Data are presented as observed. Safety assessment included all patients who received ≥1 dose of study treatment. Results Of the 274 patients who entered the extension study, 84% (230/274) completed 5 years of treatment. ASAS20/40 responses were 78.6/65.2%, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response was 63.4% and mean (±SD) BASDAI total score was 2.6±1.76 with secukinumab 150 mg at 5 years. Improvements in efficacy outcomes were sustained through 5 years. A total of 82 patients on secukinumab 75 mg (56.2%) had their dose escalated to 150 mg after week 168; ASAS40, ASAS-PR, ASAS 5/6 and BASDAI50 responses were improved in patients whose dose was escalated from secukinumab 75 to 150 mg. Secukinumab was well tolerated with a safety profile consistent over the course of the study. Conclusions Secukinumab 150 mg provided sustained efficacy across multiple domains of AS with a favourable and consistent safety profile through 5-year treatment. Over 50% of patients required dose escalation from 75 to 150 mg and efficacy improved in these patients.
Collapse
Affiliation(s)
- Xenofon Baraliakos
- Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany
| | - Juergen Braun
- Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany
| | - Atul Deodhar
- Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA
| | - Denis Poddubnyy
- Rheumatology department, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Alan Kivitz
- Altoona Arthritis & Osteoporosis Center, Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
| | - Hasan Tahir
- Department of Rheumatology, Barts Health NHS Trust, London, UK
| | - Filip Van den Bosch
- Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.,VIB Inflammation Research Center, Ghent University, Ghent, Belgium
| | - Evie-Maria Delicha
- Immunology, Hepatology and Dermatology, Novartis Pharma AG, Basel, Switzerland
| | - Zsolt Talloczy
- Immunology, Hepatology and Dermatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA
| | - Anke Fierlinger
- Immunology, Hepatology and Dermatology, Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA
| |
Collapse
|
47
|
Laloo F, Herregods N, Jaremko JL, Carron P, Elewaut D, Van den Bosch F, Verstraete K, Jans L. MRI of the axial skeleton in spondyloarthritis: the many faces of new bone formation. Insights Imaging 2019; 10:67. [PMID: 31338670 PMCID: PMC6650523 DOI: 10.1186/s13244-019-0752-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Accepted: 05/14/2019] [Indexed: 12/17/2022] Open
Abstract
Spondyloarthritis has two hallmark features: active inflammation and structural lesions with new bone formation. MRI is well suited to assess active inflammation, but there is increasing interest in the role of structural lesions at MRI. Recent MRI studies have examined the established features of new bone formation and demonstrated some novel features which show diagnostic value and might even have potential as possible markers of disease progression. Although MRI is not the first imaging modality that comes into mind for assessment of bony changes, these features of new bone formation can be detected on MRI—if one knows how to recognize them. This review illustrates the MRI features of new bone formation and addresses possible pitfalls.
Collapse
Affiliation(s)
- Frederiek Laloo
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
| | - Nele Herregods
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Jacob L Jaremko
- Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, 8440-112 Street, Edmonton, Alberta, T6G 2B7, Canada
| | - Philippe Carron
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Dirk Elewaut
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Filip Van den Bosch
- Department of Rheumatology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium.,VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent University, Technologiepark 927, 9052, Ghent, Belgium
| | - Koenraad Verstraete
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| | - Lennart Jans
- Department of Radiology and Medical Imaging, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium
| |
Collapse
|
48
|
Varkas G, Vastesaeger N, Cypers H, Colman R, Renson T, Praet LV, Carron P, Raeman F, Devinck M, Gyselbrecht L, Corluy L, Piette Y, Lenaerts J, Thevissen K, Vanneuville B, Bosch FVD, Elewaut D. Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis: Results From Two Belgian Nationwide Axial Spondyloarthritis Cohorts. Arthritis Rheumatol 2019; 70:1588-1596. [PMID: 29740978 DOI: 10.1002/art.40551] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2017] [Accepted: 05/01/2018] [Indexed: 01/17/2023]
Abstract
OBJECTIVE To determine the link between extraarticular manifestations (EAMs) and baseline characteristics in patients with axial spondyloarthritis (SpA), and to define their potentially differential prognostic value in 2 large, independent Belgian axial SpA cohorts with distinct recruitment periods. METHODS Information on demographic and clinical characteristics and extraarticular manifestations (EAMs) was obtained from patients with axial SpA originating from the (Be)Giant (Belgian Inflammatory Arthritis and Spondylitis) cohort, which includes consecutive axial SpA patients whose data have been collected since 2010, and from the ASPECT (Ankylosing Spondylitis Patients Epidemiological Cross-sectional Trial) cohort, a Belgian registry of cross-sectional data collected between February 2004 and February 2005 from consecutive patients with ankylosing spondylitis (AS) or probable AS. RESULTS Among the 1,250 Belgian patients studied, disease duration was associated with risk of developing inflammatory bowel disease (IBD), with an increase in risk by 20% per 10 years of disease duration (relative risk [RR] 1.2, P = 0.026), and associated with risk of developing acute anterior uveitis, with an increase in risk by 30% per 10 years of disease duration (RR 1.3, P < 0.001). In the subgroup of 171 newly diagnosed patients with prospective follow-up data, higher mean C-reactive protein levels over time were demonstrated in those with acute anterior uveitis or IBD compared to those without EAMs or those with psoriasis alone (each P = 0.01). CONCLUSION The risk of developing acute anterior uveitis or IBD, but not psoriasis, in patients with axial SpA seems to increase with disease duration and appears to be linked to a higher cumulative exposure to inflammation, thus providing a possible explanation for the differential structural progression observed in those with axial SpA.
Collapse
Affiliation(s)
- Gaëlle Varkas
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | | | - Heleen Cypers
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Roos Colman
- Biostatistics Unit of the Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
| | - Thomas Renson
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | | | - Philippe Carron
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | | | | | | | | | | | | | | | | | - Filip Van den Bosch
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| | - Dirk Elewaut
- Ghent University Hospital and VIB Center for Inflammation Research, Ghent University, Ghent, Belgium
| |
Collapse
|
49
|
de Hooge M, van Gaalen FA, Renson T, De Craemer AS, van de Sande MG, Ramonda R, Fagerli KM, Jacobsson LTH, van der Heijde D, Elewaut D, Van den Bosch F. Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study. Ann Rheum Dis 2019; 78:1605-1606. [DOI: 10.1136/annrheumdis-2019-215742] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2019] [Revised: 06/27/2019] [Accepted: 07/01/2019] [Indexed: 11/04/2022]
|
50
|
Claudepierre P, Van den Bosch F, Sarzi-Puttini P, Vastesaeger N, Govoni M, Kachroo S. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort. Int J Rheum Dis 2019; 22:995-1001. [PMID: 30989813 DOI: 10.1111/1756-185x.13526] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 01/17/2019] [Accepted: 02/04/2019] [Indexed: 02/06/2023]
Abstract
AIM We evaluated the effects of anti-tumor necrosis factor (TNF) agents on health economics in ankylosing spondylitis (AS) patients. METHODS QUality of Life as Outcomes and its VAriation with DIsease States (QUO-VADIS) was a prospective observational study following bio-naïve AS patients (modified New York criteria) newly treated with golimumab (GLM) or infliximab (IFX; originator) in a clinical practice setting over 6 months. We evaluated use of concomitant medications, hospitalizations (in-patient care or acute care) and visits in day care and out-patient settings for the assessment of healthcare resource utilization (HCRU). Work productivity and activity impairment (WPAI) was assessed by the number of work days missed and quantifying absenteeism, presenteeism, work impairment, and activity using the WPAI instrument adapted to spondyloarthritis (WPAI-SpA). RESULTS Nine hundred and sixty-three patients received ≥1 dose of medication (78%, n = 751 GLM; 22%, n = 221 IFX). Mean age was 42.7 years; 61.4% were male. At baseline, the percentage of patients who reported hospitalizations (in-patient care) was 13.6%, which decreased to 3.1% at 6 months, while out-patient care at baseline was reported by 39.4% of patients, which decreased to 19.0% at 6 months. The percentage of patients receiving acute emergency at baseline reduced from 1.6% to 0.3% at 6 months. The mean (SD) number of days of work missed due to AS, was reduced from 6.3 (31.1) days at baseline to 2.7 (12.3) days at 6 months. CONCLUSION In patients with AS newly treated with GLM or IFX for 6 months, HCRU was reduced and work productivity and activity increased.
Collapse
Affiliation(s)
- Pascal Claudepierre
- Department of Rheumatology, Henri Mondor Hospital, APHP, and Université Paris Est Créteil, Créteil, France
| | | | | | | | | | | |
Collapse
|